Automated External Defibrillators: Public Access

Alex Norris Excerpts

Thursday 18th November 2021 Westminster Hall

[Alex Norris (Nottingham North) (Lab/Co-op)]

It is a pleasure to serve with you in the Chair, Mr Hollobone. I, too, congratulate the hon. Member for Strangford (Jim Shannon) on securing the debate, and the Backbench Business Committee on granting it. He made a typically thoughtful case, as he did earlier in the week when we spoke about smoking cessation in this Chamber. I plan to borrow liberally from him today, as I did then, because I know he does not mind.

The hon. Member spoke about the wide cross-section of support for action in this area. Clearly, we are a very visible demonstration of that politically, in terms of the number of people who have been able to attend on a Thursday afternoon and the parties that we represent, because the debate is so important. He also detailed a long list of organisations in civil society that have come together for action. I know that they will be watching. I hope that they get a sense from the debate of how seriously Parliament takes the issue, and how clear the commitment is for action.

The hon. Member and other colleagues raised the case of Christian Eriksen, which was a very visible demonstration of cardiac arrest, and how it can affect individuals with very little notice. It was a dreadful thing. Like the hon. Member for Gordon (Richard Thomson), I watched it with incredible sadness and fear. It was an awful thing to happen to anybody, but it happened in the best place possible—a place that had lots of kit and medical expertise. I think back to all the football that we played this Saturday and Sunday up and down the country in rural communities that do not have the same infrastructure as a major football stadium. We are here today with that risk in mind.

Other colleagues made excellent contributions. The hon. Member for Mid Derbyshire (Mrs Latham) made a point on schools. We talk a lot about personal and social education in this place. CPR, water safety and railway safety should be core parts of the curriculum, because some of our young people will need those skills, and they could save a life. That would be a valuable part of their education. The hon. Member for Delyn (Rob Roberts) made a point on having great kit out there but not knowing where it is. I will expand on that shortly. The hon. Member for Cumbernauld, Kilsyth and Kirkintilloch East (Stuart C. McDonald) made points about inequalities—something that is close to my heart. I am conscious that as challenging as some of the outcomes that we have heard about are, they are worse in poorer communities such as mine. That calls us to act.

The hon. Member for Newcastle-under-Lyme (Aaron Bell) raised the terrible case of Sam Benson, which I was not aware of. It was exceptionally saddening to hear about. I associate myself with all the remarks that he made. Sam’s colleagues clearly made incredible efforts. Sadly, they were in vain, but her colleagues will at least take comfort that they behaved wonderfully in that situation. Perhaps we need to do more to ensure that others in similar situations will have access to the right kit as soon as possible. As he said, time can have a really significant impact on outcomes.

I know that the debate is a joint enterprise between the hon. Member for Strangford and the hon. Member for Sedgefield (Paul Howell), who made a point about St James’s Park. I married into a family of Newcastle season ticket holders, and that case was very visible. Again, it was perhaps the right place for such a thing to happen because of those who were around, although we would never wish for it to happen to anybody. The point that the hon. Member for Sedgefield made about the 300 school children was sobering. Again, that shows why public buildings such as schools would be very good for this sort of thing.

Heart and circulatory diseases account for one death every three minutes in the UK. We know that many cardiac arrests take place in hospital settings, but more than 30,000 take place outside of them and the survival rate for those is less than one in 10. In parts of the country, including the east midlands, the rate is lower. It has a range of causes, but whatever happens there is disruption to electrical activity in the heart, meaning that it is not pumping blood to the brain, lungs and other organs. That can lead to unconsciousness and, if left untreated, death, but advances in medical technology have given us the crucial tool of automated external defibrillators.

AEDs offer a lifeline to those suffering cardiac arrest because they provide an electric shock to the heart to restore normal rhythm. As colleagues said—I do not think that we can say this enough, because we need it to be understood more widely—they are very safe to use. They are portable and easy, they have clear instructions, and they cannot allow the user to give an accidental shock and hurt somebody, which I thought the hon. Member for Sedgefield made very clear. We cannot say that enough—I hope the people watching will get that picture. The statistics bear out how effective they are. If a defibrillator is attached to a patient by a non-medical first responder, the average survival rate is 40%. Other research puts the figure even higher. Every day, people doing extraordinary actions can be very effective indeed.

At the moment, only one in 10 out-of-hospital cardiac arrests involves a public access defibrillator. The British Heart Foundation say that our nation’s low cardiac arrest survival rate is likely to be partly attributable to that lack of access. For this lifesaving technology to work, people must be able to access it. There are two elements to that. First, AEDs have to be there. The Bill promoted by the hon. Member for Strangford is a really good way to do that. Secondly and no less crucially, we need to know where the AEDs are, whether that is us as bystanders or the emergency services. It is estimated that there are 100,000 AEDs in the UK, but only 30,000 are known to ambulance services. That is a big gap in our response. As hon. Members have said, when a person suffers cardiac arrest, it is a race against the clock. A person’s chance of survival decreases around 10% with every minute that passes.

Progress has been made, which we should say with some pride and with optimism for the future. I pay tribute to the British Heart Foundation, SADS UK, the Oliver King Foundation and others who campaign and have campaigned tirelessly over the years to improve the provision of AEDs and to provide training on how to use them. I also pay tribute to all those businesses and engaged citizens across the country who have done sponsored runs or bake sales, or put some of their business’s own money into making AEDs available. It very much shows the best of Britain and a community response—a truly selfless act. With them having done all that, we can meet that ambition in this place to push things a little bit further.

We know it can work. Colleagues have used various different international examples—I will use one of my own. Across the North sea, in the Netherlands, they created a national network of available AEDs and a system to alert trained citizens to cardiac arrests. When it comes to out-of-hospital cardiac arrests, the Netherlands has the highest survival rate in Europe, which points us in the right direction. The hon. Member for Strangford has himself pointed us in the right direction with his Bill.

We know about the vagaries of trying to get business proceeded with on Fridays—we may well see that again tomorrow. Whether or not the Bill can progress, we have the Health and Care Bill in the House at the moment, with its Commons remaining stages on Monday and Tuesday next week, I believe, and with Lords stages to come too. If the Government were minded to pick up the sentiment and theme of what the hon. Gentleman has set out, although I cannot speak for him I suggest he would be quite enthusiastic about that, and the Opposition would certainly be very supportive of it. I believe there would be widespread support across the House. There is clearly cross-party support for the common goal of an active network of AEDs, with citizens knowledgeable about their location and able to use them. We will support the Government in any measure they bring forward to make that a reality.

Tobacco Control Plan

Alex Norris Excerpts

Tuesday 16th November 2021 Westminster Hall

[Alex Norris (Nottingham North) (Lab/Co-op)]

It is a pleasure to serve with you in the chair, Mr Bone. I add to colleagues’ congratulations to the hon. Member for Harrow East (Bob Blackman) on securing the debate, and on his leadership on this issue in Parliament through the all-party group and beyond. He made an outstanding case in his opening speech and set the tone for a debate that will, I hope, be practical and impactful.

The hon. Gentleman characterised his all-party group as a critical friend. That is very much the case, and in that sense it is the best example of a parliamentary group. It has been very impactful, especially through its most recent reports, which I will borrow from liberally. I hope to continue in the spirit of cross-party support that he and my hon. Friend the Member for City of Durham (Mary Kelly Foy) have established. There is not much politics in this area, and I think the less politics, the better. This is a big prize for the nation’s health, and together we can find a lot of the solutions. The hon. Gentleman led the debate in that spirt.

My hon. Friend the Member for City of Durham is the leading Labour figure on this issue, as she showed during our very long proceedings in the Health and Care Bill Committee—you shared in a significant portion of those, Mr Bone. I thought her amendments were excellent and I was proud to support them. I had hoped that the Government would be minded to accept them, and the ideas are still good ones. The hon. Member for Harrow East has kindly offered the Minister another opportunity to do so during the next stage of proceedings on the Bill, and I dare say the noble Lords may offer similar opportunities. The Government need to pick up these ideas, the vast majority of which are very basic things on which I think there is complete consensus. I hope to hear from the Minister about some progress.

The hon. Members for Rugby (Mark Pawsey) and Northampton South (Andrew Lewer) made points about vaping. It is important to keep talking about vaping in debates such as this—if nothing else, about some of the misinformation that the hon. Member for Northampton South mentioned. Vaping does work as a quit aid. Of course, we do not want people to start, and we always need to say that. I am unable to recall by rote the phrase that the hon. Gentleman’s wife used, but I will sometimes take 95%, certainly when it comes to health. With the things that my constituents disproportionately lose their lives to, 95% seems like pretty good progress. I hope that that is part of the tobacco control plan, and that the Government focus on improving quality and standardisation in the market. From looking in shops, I know how difficult it is to find the same product twice. That tells us about the vagaries in that market, which could be greatly improved.

When the hon. Member for Strangford (Jim Shannon) was speaking, I was struck by the fact that much of what he said about Strangford could equally be said about Nottingham North. He could have said “Nottingham North” instead of “Strangford”, and we would have heard the same thing. Health is a devolved matter, and it is important to respect that, but I hope we can move forward, by consent, as four nations on this matter. That would resolve some of the issues around illicit tobacco mentioned by the hon. Member for North Antrim (Ian Paisley), as well as building public support and understanding. We would not want massive variances on this issue, so I hope we can reach a consensus.

I agree with the hon. Member for North Antrim that we need to be evidence-based and to promote innovation. In my view, the evidence strongly shows that tax works as a driver for reducing smoking, and it has done for consecutive decades. I am not blind to the increased risk of illicit tobacco and I am aware of it in my community, but I do not see this as an either/or situation. We can have a higher tax regime and be very serious about organised crime, and I would support that approach.

This is a really big prize for our country. As we have heard, 7 million people, or about 15% of adults, smoke, which has devastating consequences for illness and death. In 2019-20, more than half a million UK hospital admissions were attributed to smoking. We have made great progress over recent decades—that should be a point of great pride for all parties—and we have the lowest rates of smoking since records began. However, there must be a recognition that these gains are not equal, and I hope the Minister will say that that will be a focus for the next tobacco control plan.

Poor communities, such as mine, have benefitted less. In 2019, fewer than one in 10 professional and managerial workers smoked—that is well on the way to the smoke-free 2030 target of less than 5%—compared with nearly one in four workers in routine and manual occupations. That is a serious variance, and it is a big part of the reason why the life expectancy gap between the richest and the poorest has widened in recent years.

A child born in Nottingham today is expected to live for seven years fewer than one born in Westminster today. Looking at healthy life expectancy, rather than pure life expectancy, the gap is probably double that. If we were to tot up all the environmental factors involved, half of the difference is attributable to smoking. “Levelling up” is the phrase of the day, and this is a real levelling-up issue that I hope we can all coalesce around. That is reflected in the fact that three quarters of the public support the smoke-free 2030 ambition. As politicians we can see that, for once, the right thing is also the popular thing, which is rarely the case. We should take that opportunity.

In Health and Care Bill Committee debates, we explored these issues at length. I hope the Government will revisit the amendments that were proposed, and we will certainly be doing so. I hope the Minister will tell me that I am wrong and being uncharacteristically cynical, but I am anxious that we will not see a new tobacco control plan in the next six weeks. If that is the case, why not use the Health and Care Bill in front of us as a vehicle?

As the Minister is pulling together a tobacco control plan, I hope she will actively consider some of Opposition Members’ suggestions for that plan. First, there must be a resumption of the promotion of stopping smoking. Over the past 11 years, this Government have stopped evidence-based behaviour change campaigns, which have virtually disappeared. It is no surprise that quit attempts have reduced by a quarter. Such campaigns are good investments, and we have lost them from the public health grant. We need them to be returned.

I mentioned vaping, and that point has been well explored. We need access to stop smoking services, which have really good evidence bases on their impact. We know that they are most likely to be used by people in occupations where smoking remains stubbornly high, but we have lost them as the public health grant has been clobbered over the past decade. I know for an absolute certainty that any savings we have made there have been hoovered up by losses in the health service, and I hope we can do a bit better there. Three weeks ago, in the Budget, we did not hear about a reversal of those cuts in funding to public health, and that is really disappointing. However, if there is a financial issue here—as I say, I do not think there should be, because this should be seen as an investment rather than a cost—we can, as colleagues have said, help the Minister to pay for those services and still have some change left over for an uplift in the poorest communities through a levy based on the “polluter pays” principle. I hope that the Minister will mention that.

The hon. Member for Broxbourne (Sir Charles Walker) asked the hon. Member for Harrow East whether the tax system could be a way of promoting changes within the tobacco industry. I think that is exactly right. When I meet representatives of the tobacco industry—I know it is out of fashion these days, but I meet anybody who asks me to meet them—they all tell me that they want to stop selling tobacco products to people. The tax system is a really good way of making good on that, and of taking the eye-watering profits that come through the system and investing them in effective ways of stopping people smoking. That would be a very good thing for everybody.

In the meantime, however, let us close the loopholes in tobacco control. The first, as my hon. Friend the Member for City of Durham says, is that the packaging of e-cigarettes clearly shows they are being pushed to children. Secondly, hon. Members were shocked—although they should not be—that companies can give out vaping products to under-18s for nothing. That loophole is clearly outside of the spirit of the law, so let us do better there. The final point is about characterising flavours in tobacco, such as menthol. That should be a real problem for the Government, and indeed for Members of this House. The regulations that we passed had a clear intent, but they are being routinely circumvented to the point where, if hon. Members had their phones in front of them, they could find menthol products in seconds. This will not do, and it behoves the Government to come back to those regulations and make good on them, either by making them more effective or by promoting greater enforcement.

I know that colleagues are keen to hear the fullest response possible from the Minister, so I finish by reiterating Opposition Members’ support. I think we can do something really impactful here, and we should use this tobacco control plan to do so. The sooner we see a draft, the better, so we can begin that work.

Draft Food (Promotion and Placement) (England) Regulations 2021

Alex Norris Excerpts

Monday 15th November 2021 General Committees

[Alex Norris (Nottingham North) (Lab/Co-op)]

It is a pleasure to see you in the Chair, Mr Stringer.

The regulations are the latest part of the Government’s obesity strategy to come through the system. The official Opposition have so far been quite gentle with the Government about the strategy because, although it is modest and misses many impactful elements, we want it to happen, so we have sought not to scare off the Government from acting. That is also true for issues of promotion and placement, but it is hard not be a little disappointed, as I shall set out shortly.

The case for change in this area is strong. The UK has among the highest childhood obesity rates in western Europe. One in four children is overweight or obese when starting primary school, and the number is one in three by the time they move on to secondary school. These children are more likely to become obese adults—at present, one in four adults is obese—and therefore to be at risk of diabetes, heart disease, fatty liver disease, cancers and mental health conditions. The situation is worse in poorer communities such as mine. Indeed, one in three adults in the most deprived areas is obese, compared with one in five in the least deprived. The discrepancy among children is even more alarming: more than twice as many children are obese in the most deprived communities compared with the least, and that gap has nearly doubled under this Government.

It is important to state that any health improvements arising from the regulations, or indeed from the entire obesity strategy, will be knocked into a cocked hat by the impact of the cut to universal credit, which will push those with the least back on to cheaper and less healthy food options. There is therefore a disconnect between the regulations and the rest of the Government’s policies.

The regulations control high fat, sugar and salt food and drink. Such products can be part of a balanced diet, but their regular overconsumption has a significant impact on people’s health and wellbeing and leads to the diseases that I listed. There is no doubt that in-store promotions are incredibly effective in influencing what people buy. As the Minister said, people buy 20% more than they intended due to promotions. Again, that hits the poorest hardest, because they do not realise savings from that approach; they just consume more.

Cancer Research UK has shown that greater volumes of HFSS are likely to be purchased by those who are overweight or living with obesity, so there is a direct correlation between promotions and obesity. It is therefore right to take action to address the situation, not by limiting people’s freedom of choice, but instead by supporting them to make healthier choices. The public are aware of the issue and support change. I note from the regulations’ impact assessment that the majority of consultation responses were positive about such an approach, and academic evidence supports it.

I want to explore some practicalities with the Minister. First, this is to be enforced by local authority trading standards. The Government have slashed resources for trading standards over the last 11 years, including only three weeks ago in last month’s Budget, so I hope the Minister will tell us what assessment she and her officials have made of the capacity of local authority trading standards to enforce any of this. Similarly, I have received many concerns—I am sure other Members have too—from representatives of the business sector about questions that they think the Government have not yet addressed. Indeed, the Food and Drink Federation, the British Retail Consortium and the Association of Convenience Stores have compiled a list of 25 priority questions. I hope the Minister will commit today to engage properly with those organisations and to address each of those questions.

I have some questions of my own for the Minister. The new rules will apply, as she said, to medium and large entities. This is a mirroring caveat to those introduced in the Calorie Labelling (Out of Home Sector) (England) Regulations 2021, which we dealt with in the summer. They made sense in that case because requiring smaller businesses to calculate the calories in their products and provide bespoke menus to demonstrate that would have been an onerous responsibility. That would apply to the placement element of these regulations, because if a business is smaller it will be harder not to have things near the till. That seems fair. But why does it apply to promotions? Why is it more onerous for small businesses rather than medium businesses or franchises to not provide a three-for-two or a buy one, get one free? I think of my own childhood: if we wanted to buy cigarettes before we were allowed to, we knew the shops that would sell them to us. Similarly, I fear that children will know, because they are crafty, the difference between an independent shop that can sell two for one and a chain shop that cannot. That will create a market disruption that will undermine the goals of the regulations. I would be interested to hear the Minister’s thoughts on that.

On the timeline, the Minister said that she wants to support businesses to make sure that they can do this. There is a strong sense from the sector that October 2022—less than a year away—will be too soon to implement it. It will be costly and complex, and businesses are asking for a six-month delay. Normally, my instinct would be to say, “Well, in the case of health and wellbeing, we need to get on with it and business will be creative and find a way.” But in this case, we have asked these same businesses in the last year to reconfigure their stores to make them covid secure for staff and for customers, and they have stepped up and done a magnificent job. We are now asking them to do a secondary configuration, still within the covid-secure measures, and perhaps then another reconfiguration after covid security is no longer needed. That is quite a big ask, and I am keen to hear from the Minister whether the Department has considered that. If not, will she engage with the industry to talk about the timelines?

The detail of the regulations will be in the guidance. We respect that some of the more technical issues, such as what constitutes a specialist store or what is a meal deal—an existential question for the 21st century—will not be on the face of the regulations, but we are asking business to make a really significant change in 11 months’ time and we still cannot tell them now what changes we will ask them to make. They will need to know the details to give them even a fighting chance of making that deadline. In which case, can the Minister say when the guidance will be published, because the sooner that can be done the better?

My final point is one of great frustration that the regulations are not as good as they could be for many of the reasons that I have just mentioned, including handling the issue through secondary legislation. Recently, I and other colleagues—including the Minister, for a while—spent weeks just down the corridor dealing with the Health and Care Bill in Committee for sitting after sitting between the beginning of September and the end of October. Part 5 of the Bill included elements of the obesity strategy, especially the advertising ban, and that gave us the opportunity to table amendments, take evidence and have full discussions of those provisions. We will have similar opportunities to improve them in the remaining stages and in the Lords. Why were these draft regulations not treated in that manner? If we had done that, we would have pursued many amendments, because there are holes in the regulations. Instead, however, we have been given a take-it-or-leave-it proposition.

We will not vote against something that we think will have a positive impact on the public’s health, but I hope the Minister—she is relatively new to her role and I know her well from our east midlands work—will be reflective about her practices and those of her Department. The ban on flavoured tobacco was pushed through in a similar manner, but fundamental questions were not really addressed. There was not an awful lot of engagement with business or political colleagues, and the thing has not worked—there are workarounds—because the regulations contained gaps that Ministers could easily have been helped with. However, due to a lack of flexibility and pragmatism those gaps were not closed and the ban has not worked, and Ministers will eventually have to return to the matter. I fear that today’s draft regulations will face the same fate, because the workarounds are quite clear.

I will not impede the proposal’s progress today, but the Opposition are disappointed, and I hope the Minister may address some of our disappointments in her closing remarks.

Giving Every Baby the Best Start in Life

Alex Norris Excerpts

Tuesday 9th November 2021 Commons Chamber

[Alex Norris (Nottingham North) (Lab/Co-op)]

I am grateful to the hon. Member for Richmond Park (Sarah Olney), the right hon. Member for South Northamptonshire (Dame Andrea Leadsom) and my hon. Friend the Member for Newcastle upon Tyne North (Catherine McKinnell) for securing this debate. The collective case that they made was weighty, and I think there was universal agreement; I certainly did not disagree with anything that was said.

I associate myself with the comments made by the hon. Member for Richmond Park about the importance and the centrality of good health visiting. She also made very interesting points about lockdown and covid that were shared by the hon. Member for Strangford (Jim Shannon) and the right hon. Member for South Northamptonshire, whose statistic that seven in 10 parents feel that they have not had enough support was sobering. That shows the scale of the challenge that we have in building back.

Of course, the right hon. Member has also gifted us her rich report, which we are discussing, in many ways, today. I want to take this opportunity to reiterate in public what I have said to her in private about the Opposition’s support for her. She had real success at the Budget, which we were all heartened by. We know there is more to do, but she is clearly doing something right and, as I say, we will be with her along the way.

My hon. Friend the Member for Newcastle upon Tyne North made a stark and powerful speech about poverty. She could have changed Newcastle upon Tyne North to Nottingham North—my constituency—and the entire thing would have read across, but particularly the cruelty of pre-ordaining a child’s destiny at their birth.

The hon. Members for East Worthing and Shoreham (Tim Loughton) and for Ruislip, Northwood and Pinner (David Simmonds) talked about turning the strategy into a local plan and putting an emphasis on local authorities or health and wellbeing boards—in my case, I think integrated care systems is the model. I proposed that in a new clause that I tabled to the Health and Care Bill, which the Government were not minded to accept. I hope that we might be able to work together on that, and that we might get something in the Bill to that effect in its remaining stages. I think that would be a very good way to do that.

I pay special tribute to my hon. Friend the Member for Washington and Sunderland West (Mrs Hodgson), my predecessor in this role, because so much of our policy is her policy and I have just been carrying on that work. The point she made about the environment was one I had not heard her make before. I am always fearful that children can sometimes grow up in hopeless environments and the future of the planet is one of the things that restricts hope. That is a very important point and we have a responsibility in this place to address it.

My hon. Friend the Member for Pontypridd (Alex Davies-Jones) made the point that, if in doubt, look at Wales. In many ways, that is very much the way to go.

Previously, and certainly for the last 10 years, the place to start when talking about early intervention and the best start in life was the breakthrough 2011 report on early intervention by my friend and constituency predecessor, Graham Allen. Happily, the right hon. Member for South Northamptonshire is providing him with some good competition with her report. As we have seen in the debate, that has established a cross-party consensus to make good on this. The report confirms and builds on what we know about how critical the first 1,001 days are.

In my maiden speech four-and-a-half years ago, I talked about similar themes for my community and how these challenges are cyclical, and said that the way to break those cycles is to intervene as early as possible. A healthy pregnancy is very important for mum, but also for the baby’s development. Beyond specific dangers such as smoking, alcohol or drugs, we know that stress can cause challenges for babies. That is an awful lot of pressure on mums, so health visitor support is really important, as the hon. Member for Richmond Park said. The next two years are crucial, too, in setting out how a child’s life is likely to go. The hon. Member for Bath (Wera Hobhouse) made important points about adverse childhood experiences, which we know have a lifelong impact. As I say, the case for change is well established, but we have to have concrete things to do and the report and the six action areas effectively laid out that route for us.

I want to briefly address Sure Start. We know that Sure Start prevented hospitalisations, impacted children all through their adolescence, improved mental health, helped particularly in the poorest communities and, of course, made major, long-lasting savings for the NHS. The tragedy is that any savings made by cutting those services will be hoovered up in costs to the NHS. It is dreadful public policy. I say that not to litigate the events of the last 10 years, but because at the moment councils are setting their budgets. Councils in cities such as mine will be making decisions that mean children’s centres will again be lost. So we have not adequately addressed this yet. It was not adequately addressed in the support for local authorities in the Budget. Family hubs are very welcome and I accept the point that they are not a like-for-like replacement, but my point is that we are weakening our approach in this area by filling the bath at the top and then draining it at the bottom. I think that is a big mistake.

I will make a final point on what I consider to be our greatest hurdle in this endeavour: the public finances and the Treasury. This is the sort of spending that we know—the hon. Member for Ruislip, Northwood and Pinner said this—benefits future generations. Politically, I think we can get our heads around that. The previous Labour Government showed that we can do that. The growing consensus is that we want to make long-term investments, even if we are not in this place seeing the benefits from them. However, I do not think we have quite got there yet with regard to the Treasury. Clearly, significant progress was made at the Budget—I want that to be recognised—but we need models that, for the Treasury’s purposes of balancing the budget and having good responsible public finances, also recognise that investing now can give returns in a decade. Even if we are not able to get the pound and penny of where that return will be, we know that it will happen. I do not think we are quite there yet and I would be very interested to hear the Minister’s thoughts on that.

The report by the right hon. Member for South Northamptonshire has set us a real road map. A political consensus is being established around it. However, we now need to know the long-term commitment. On the Labour Benches, we are committed in finance and in public policy terms to make the investments here. The Government showed at the Budget that they are starting to get to that place, but I hope to hear from the Minister that that is for the longer term and not just a one-Budget commitment. The prize is so great for our nation. As a result, our ambition must be great, too.

Medical Cannabis: Alleviation of Health Conditions

Alex Norris Excerpts

Thursday 4th November 2021 Commons Chamber

[Alex Norris (Nottingham North) (Lab/Co-op)]

I thank the Backbench Business Committee for granting this important debate and the hon. Members for Inverclyde (Ronnie Cowan), for Edinburgh West (Christine Jardine) and for Reigate (Crispin Blunt) and my hon. Friend the Member for Gower (Tonia Antoniazzi) for securing it. I also thank the cross-party campaigners in this place beyond that group, including the hon. Member for South Leicestershire (Alberto Costa), the right hon. Member for Hemel Hempstead (Sir Mike Penning) and my hon. Friend the Member for Manchester, Withington (Jeff Smith), for all that they have done over the years to put it on the parliamentary agenda.

Progress in making cannabis-based medical products available to those who need them has been slow, so it is right that we have the opportunity to debate the frustrating lack of progress. As hon. Members have said, this is the second debate in two days, which I hope gives those watching confidence that we in this place are taking the issue seriously.

I associate myself with the remarks of the hon. Member for Inverclyde in his opening speech about the families who are dealing with incredible, unthinkable challenges and who handle themselves with such dignity and make such powerful cases. I hope—I feel—that we have done them justice today and will continue to do so. In particular, I hope that the Minister will touch on his points about the limiting factors in research.

The speech of the hon. Member for Reigate was a characteristic tour de force. I always stop to listen when he is talking about the issue, because he speaks with such power. He made the point that it is unacceptably cruel to take effective medicines away from a child, which we all agree with. He linked that to palliative care, and I share the view that we want people at the end of their life to get whatever treatment might make their final days the best that they can be. Actually, that applies to adults throughout their lives: if people are living in pain and do not have to be, I would want to do anything I could to avert that.

The hon. Gentleman spoke about the 2018 regulations and the sense that we thought they had solved it, as the right hon. Member for New Forest East (Dr Lewis) also said. The hon. Member for Reigate gave us a hopeful way forward by concluding that we need to be creative and solution-focused. The Opposition share that view—I do not think there is a lot of politics on this issue—and support coming together to find a practical, effective, safe and risk-aware solution.

My hon. Friend the Member for Manchester, Withington spoke in that spirit. He is fortunate to have been drawn in the private Member’s Bill ballot, which is precious for any right hon. or hon. Member. He is keen to work with the Government. I know him well and know the spirit in which he will work with them, so I hope the Minister will take that up. That private Member’s Bill would be a perfect vehicle to move the issue forward. His point that it is about not just epilepsy was well made. I double underlined the phrase that we need to give clinicians the “comfort to prescribe”, which was elegantly put. I completely support that goal and will come back to it.

The hon. Member for Edinburgh West spoke about her constituency case of Murray. Many right hon. and hon. Members will recognise similar cases in their surgeries. The daftness of that story is that the UK’s prescribing could grind to a halt on the basis of a single person retiring. Where else in the health service would that ever be the case or tolerated? It is an absurd set of affairs.

My hon. Friend the Member for North Tyneside (Mary Glindon) kindly facilitated the opportunity for me to meet her constituent, who is a doughty campaigner, as she says. To hear the impact on her constituent’s life, it is hard to understand why we are not doing everything we can to make sure that she can live with as little pain as possible. I will get on to the counterargument about the lack of evidence, but she is that evidence, because we know what her life was like before and after, so I find that argument hard to accept.

The common theme of the contributions has been frustration or, more positively, a desire to redouble our efforts in this area, which cuts both ways. There are opportunities in research, which I hope the Minister will talk about, with regards to epilepsy, long-term pain relief and mental health. We also need a stronger position on the regulation of products such as cannabidiol, which proliferate on the internet and can be found in various shops, in all sorts of forms, promising all sorts of things that are hard to establish. We need better regulation in that space.

When the Government accepted the therapeutic use of cannabis, it was met, as we have heard, with much relief from campaigners, such as the families of Billy Caldwell and Alfie Dingley, who has now gone 508 days without an epileptic fit thanks to his medicinal cannabis treatment. It has changed his life, but not everyone has been so lucky.

Bailey Williams has been denied access to medicinal cannabis for his epilepsy and his parents are forced to raise £1,200 a month for his treatment. The mother of 11-year-old Teagan Appleby spends about £2,000 a month to treat her daughter’s Lennox-Gastaut syndrome, as she has not received a prescription. In the time that she has been taking that treatment, she has to go to hospital only once—when it ran out. That is the impact on her life.

I think of my constituents and how few, if any, could spare £2,000 a month. Of course, all of them, and I daresay all of us, would go to whatever lengths necessary for our children—that is the tragic paradox—but it is not acceptable. We are letting people down on an issue that we thought we had resolved.

In 2018, cannabis-based products were rescheduled. Guidelines were produced by the National Institute for Health and Care Excellence and three products got through: Epidyolex for rare forms of epilepsy, Nabiximols for multiple sclerosis-related spasticity and Nabilone for side effects from chemotherapy. The regulations said that initial prescriptions must be made by a specialist medical practitioner and, in all cases, would be considered only when other treatments were unsuitable or had not worked.

[Dr Lisa Cameron (East Kilbride, Strathaven and Lesmahagow) (SNP)]

The hon. Gentleman is making an excellent point. Does he agree that the psychological pressure and stress of having to campaign constantly and raise money at that level is simply unfair? My constituent Lisa Quarrell has had to raise thousands of pounds for her child Cole Thomson and has been under that stress continually for years. It is time for us to work collectively to overcome any hurdles to achieving success.

--- Later in debate ---

[Alex Norris]

I have seen the fundraisers online, as other hon. Members will have. When people have to raise that amount of money each month, they must not be able to do anything else and they must live with that anxiety constantly. We want to relieve people of that as far as we can.

We know that the number getting through has been dreadfully low. The previous Minister said in February that 413 unique eligible patients had been identified, but no estimate had been made of the number who had received prescriptions. End Our Pain believes that only three prescriptions have been issued on the NHS—goodness me, that is not what we thought it would be three years ago. If the Minister has more up-to-date information, we would be keen to hear it, but there is definitely a sense that it is not going anywhere near far enough.

Last year, a Care Quality Commission report found that a meagre 6.5% of cannabis-based items were prescribed on the NHS. Again, that is a paradox because we are told that there is real anxiety about prescribing it, but if people pop it into a search engine, they can find an awful lot of private treatments that do not seem anxious at all—there seem to be fewer shy bairns there. I am not sure that that is quite the defence that those who use it think it is.

It is a matter of justice if people are missing out or are left with the horrendous choice between paying over the odds for medication and suffering. The founding principle—the settled political point—of the national health service is that we do not tolerate that or think that people’s access should be based on their ability to pay, but we are tolerating that here, so I hope we can do better.

[Dr Julian Lewis]

I have been looking at the Hansard of yesterday’s debate—there is an opportunity for the Minister to refer to it when she makes her remarks—and I see that one of the main points she made yesterday was the fact that there is insufficient evidence on the safety aspects and the possible harm effects. Given that families are paying all this money and finding other ways of getting the cannabis-based products, would it be a way forward if families were asked to sign a waiver if it were prescribed, so that the people doing the prescribing would be protected against any subsequent action if in fact something went wrong? It might be for the family to take that decision on the balance of benefit and harm.

[Alex Norris]

I am grateful for that intervention. I am slightly torn in the sense that I have absolutely no doubt that families would take it on that basis, but as a former trade union official, I would never have advised a member to sign away their rights. I think that is what we are getting at when the hon. Member for Reigate says that we have to come up with something creative that means we can clear this hurdle, and that is one such option.

Let me link that back to a previous intervention by the right hon. Member for New Forest East on opiates—if you will briefly indulge a thought experiment, Mr Deputy Speaker. If the reverse were true and we routinely prescribed cannabis-based products to deal with pain issues, would anybody really be advocating at the Dispatch Box that we should instead swap them for opiates and that they would be a better alternative? I think the answer to that is an obvious one, and that should be guiding our thinking.

[Ronnie Cowan]

A vital point was made there about who should be prescribing this. Dr Martinez, the retiring private prescriber of medical cannabis, has written to the Secretary of State for Health and, on the group she prescribes for, she said:

“I know that a majority of the GPs dealing with this group of children wish to prescribe, but, in order to do so, this requires a change of policy from the Health Department because it is CBD medication which has been treated differently to other controlled drugs.”

The solution is there. I get the point that parents can agree to a waiver, but they should not have to. This can be changed, and the Secretary of State for Health has been asked to do this by a consultant.

[Alex Norris]

That is very handy timing from the hon. Gentleman because I was just about to make that point. Following that retirement, Robin Emerson, the father of Jorja Emerson—he is behind the Jorja Foundation and has been campaigning tirelessly—has written to the Secretary of State and the Prime Minister asking them to intervene, but my understanding is that he is yet to receive a reply. I hope the Minister will commit to that being immediately addressed because this is very important indeed.

I will make a couple of final points before I finish. I listened very carefully to what the Minister said in the debate yesterday—we are in a novel position of having them on consecutive days, which is helpful—and it is clear that the Minister considers it a clinician issue rather than a political one, but that is not working at the moment. We are in a strange situation of there being so much concern about the nebulous long-term effects of these prescriptions that that is seen as better than, say, leaving a child fitting 100 times or more a day. It is rather like not throwing a rope to a drowning person for fear of their burning their hands on it. I find that hard to imagine, but we are in such a situation.

I fear that merely putting this at the door of clinicians is defending the status quo. I feel that we in this place do have agency and, indeed, a responsibility to act. I hope to hear from the Minister that there is going to be a greater drive from the Department to encourage clinicians. My hon. Friend the Member for Manchester, Withington offered suggestions on the training that I know is out there, and again I am keen to hear what we can do to have that picked up more reasonably.

Across this debate and the debate yesterday, clear themes have emerged: better research, or perhaps creative research, as the hon. Member for Edinburgh West said; better engagement with clinicians, again with the points my hon. Friend the Member for Manchester, Withington made; and, for goodness’ sake, immediate relief for families in the system now. They are going through things we would never tolerate for ourselves or would absolutely hate for ourselves, and I feel we that have a real responsibility to step that up.

I think there is broad consensus on this, and we now need to come together on a flexible solution to do it. Just as the SNP spokesman, the hon. Member for Stirling (Alyn Smith), said, we will support the Government if they bring that forward. This is something I think we all share, and the families are watching us and waiting for us to do it.

Health and Care Bill (Twenty Second sitting)

Alex Norris Excerpts

Committee stage
Tuesday 2nd November 2021 Public Bill Committees

[The Chair]

As Members have possibly worked out, I am a last-minute stand-in for Peter Bone, which has always been my ambition in life. [Laughter.] Seriously, Peter has been caught up in some kind of road traffic incident. I think he is fine; he has just been delayed, so that is the reason for the delay in proceedings.

I remind Members of all the usual things: please switch electronic devices to silent, and remember that no food or drinks are permitted. I encourage Members to wear masks, as per the House of Commons Commission rules, and to give their notes to Hansard or to send them to [e-mail].

New Clause 58

Duty on NHS England to promote evidence-based public health programmes

“(1) NHS England must promote to integrated care boards the value of evidence-based public health programmes.

(2) NHS England must publish a report each year on the state of evidence-based public health programmes within England and their impact.”—(Alex Norris.)

Brought up, and read the First time.

[Alex Norris (Nottingham North) (Lab/Co-op)]

I beg to move, That the clause be read a Second time.

I have heard about the fastest gun in the west; I think you might be the fastest-moving Chair in the west midlands, Mr McCabe. Turning to the substance of the new clause, covid-19 has shown the value of public health programmes in building this country’s resilience and improving public health outcomes, yet there is no duty in the Bill on NHS England to promote such public health programmes to integrated care boards or to evaluate their impact. New clause 58 seeks to change that.

During proceedings over the past couple of months, I have highlighted on multiple occasions the damage caused by the short-sighted health cuts we have seen over the previous 11 years, so colleagues will be relieved to hear that I am not going to repeat those points. However, we should be looking to do better now and to use this Bill as a watershed moment. As the Association of Directors of Public Health noted when the White Paper was published, there is a limited focus in the Bill on the health inequalities that have been exposed and exacerbated by covid-19 and, again, this new clause seeks to improve that situation. With the changes to Public Health England and the announcement of the new Office for Health Improvement and Disparities, it is vital that the Government make a belated recommitment to public health and prevention.

There are a number of ways in which that commitment could be manifested. Public health programmes are particularly crucial to the prevention agenda, and it is right that NHS England promotes the value of those programmes, looks at them, assesses them and reports on their impact. To draw on one example that is linked to an item we will be discussing later—dental services—community dental services and oral health public health programmes have shown that significant savings and significant improvements in individuals’ lives can be generated through effective, evidence-based public health programmes. Social enterprises such as those can bring a number of additional benefits. They exist not to make a profit but to deliver on a social mission and to reinvest any surplus in improving local services.

That is what the public health grant traditionally funded. When I first had responsibility for the public health grant in 2014, 85% of that money went into commissioned services. That funding will have been diluted by the cuts in recent years, but largely that money went to community-based, not-for-profit, evidence-based schemes. Public health programmes really improved our communities, but we have lost them, and that is a sadness. We need to recommit to them and have a real focus on getting integrated care systems to commit to them, demonstrating what works in one part of the country and promoting it across the rest of the country. That is what this new clause seeks to achieve.

[The Minister for Health (Edward Argar)]

Mr McCabe, it is a particular pleasure to see you in the Chair this morning, allowing us to get going.

I very much welcome the opportunity to debate and put on record again the Government’s commitment to improving and protecting the public’s health and to supporting evidence-based interventions. Like the shadow Minister, the hon. Member for Nottingham North, I can think of no better example than the remarkable speed of this country’s roll-out of covid vaccinations and the response to the pandemic, saving lives and supporting our economic recovery. That, of course, is testament to the hard work and dedication of our NHS and public health professionals in rising to the greatest infectious disease challenge of modern times.

Our commitment to evidence-based public health is also writ large in many of the Bill’s provisions, our wider programme of public health reform and the proposals set out in the Government’s recently published plan for health and care, “Build Back Better”. We made it clear in that document that although the Government’s immediate priorities for the NHS must be dealing with covid and recovering from the elective backlog, the long-term priority is to shift the NHS towards prevention. Prevention must be a central principle in delivering a sustainable NHS and levelling up. That means fixing the underlying causes of ill health, which is at the heart of the mission of the new Office for Health Improvement and Disparities and the new UK Health Security Agency.

As new clause 58 hints at, a focus on prevention, coupled with a strategic approach to population health more generally, will also be at the heart of integrated care systems. The new triple aim will bind NHS bodies to consider wider effects on health and wellbeing, alongside a duty to reduce inequalities in access and outcomes. Integrated care boards will be required to seek advice from persons with a broad range of professional expertise on public health and prevention, complementing the role, already set out in regulations, of local government and directors of public health to provide advice. Moreover, each integrated care partnership’s strategy will be clearly rooted in, and draw extensively on, local place-based joint strategic needs assessments so that real needs and priorities can be addressed at local level. The ICB’s plans must have regard to that strategy.

I entirely concur with the shadow Minister that evidence-based public health practice is always desirable, and a learning culture essential, but the Government do not see the need for a specific legal duty on NHS England to promote that to ICBs—as envisaged by the new clause—although it undoubtedly will have a role in exhorting and supporting them to their best efforts. The Office for Health Improvement and Disparities and the UK Health Security Agency will also have an important role in this regard, and the National Institute for Health and Care Excellence will continue to issue evidence-based guidance on public health topics referred to it.

There is already a broad obligation on NHS England and NHS Improvement to promote continuous improvement in the quality of services provided across the NHS and, in doing so, to have regard to evidence-based public health quality standards. That includes having regard to quality standards prepared by NICE.

It follows from the rejection of the first limb of the new clause that the Government cannot support the second. However, as set out in “Build Back Better” the Government will bring forward separately from the Bill a new requirement for NHS England

“to introduce a yearly prevention spend, outcome and trajectory reporting criteria, including an assessment of the 10-year spend and outcome trajectories…of the major preventable diseases such as diabetes.”

It may not, but I hope that that goes some way towards meeting the intent behind the shadow Minister’s new clause.

There is a somewhat different matter where public health programmes are commissioned directly by the NHS itself, in exercise of the Secretary of State’s public health functions. That is the case with, for example, national screening or immunisation programmes. These programmes are currently commissioned by NHS England but are rooted in expert advice from the UK National Screening Committee and the Joint Committee on Vaccinations and Immunisations respectively. NHS England is already prepared to report to the Secretary of State on its performance against these functions.

Were any of these functions to be delegated to ICBs to deliver in future, we would expect NHS England to clearly convey the requisite standards and performance expectations for those evidence-based programmes, and overall information about performance and effectiveness will be provided to the public.

In summary, there is a good deal of unity of aim and objective, but I fear there is a difference as regards methods. On that basis, I encourage the shadow Minister not to press the new clause to a Division.

[Alex Norris]

I share with the Minister the desire for a shift to prevention. My anxiety, from the Government action we have seen over the last decade, is that that is a rhetorical shift rather than a substantial shift in policy, and definitely not a substantial shift in resourcing. Nevertheless, the Minister’s answer on the documentation that NHS England will be asked to publish is a suitable substitute for a provision being on the face of the Bill. On that basis, I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 63

Young carers’ needs assessments following hospitalisation

“In the Children Act 1989, after section 17ZC, insert—

‘17ZCA Young carers’ needs assessments following hospitalisation

(1) An NHS trust or NHS foundation trust must ascertain during hospitalisation whether a patient when discharged will be cared for primarily by a young carer.

(2) Where an NHS trust or NHS foundation trust ascertains that a patient when discharged will be cared for primarily by a young carer then the NHS trust or NHS foundation trust must give the local authority where the patient lives notice that a young carer will require a needs assessment.

(3) The local authority receiving notice under subsection (2) must carry out a needs assessment, and in doing so must—

(a) ascertain whether it is appropriate for the young carer to provide care, and

(b) identify what support or services need to be in place for safe discharge of the patient.

(4) The needs assessment required by subsection (3) must be conducted before the patient is discharged.’”—(Karin Smyth.)

This new clause would ensure that the needs of young carers are assessed before a patient who they care for can be discharged.

Brought up, and read the First time.

[Karin Smyth (Bristol South) (Lab)]

I beg to move, That the clause be read a Second time.

It is a pleasure to see you in the Chair, Mr McCabe. I will not delay the Committee too long on this new clause, but it is an important one to consider. We had a good discussion last week on the needs of carers, although I am not sure we resolved it satisfactorily. Carers do a huge amount of work on behalf of their families. As my hon. Friend the Member for City of Durham so eloquently said, they want to do that work, but many of them essentially keep our services going. Without them, the demands on our services would be so much greater.

[Mr Peter Bone in the Chair]

All of us who have met or who know young carers recognise the particular stresses and strains on them from caring for their relatives. They do astonishing work. Again, as my hon. Friend said, many feel that they are doing it because these are their loved ones; they do not feel like they are carers in many cases, but they are. Often people then do not come forward, if they are not known to the authorities, to make that clear. That is often because of fear of what that might mean for the family set-up they find themselves in.

The new clause draws attention to the needs of young carers, particularly following hospitalisation. It would require trusts and local authorities to be cognisant of who is caring for a person when they are discharged, particularly where young carers are involved. When the issue was first drawn to my attention—particularly the need to highlight the different needs of young carers—I must confess that I thought that these things were routine in good care settings. Obviously, the situation into which someone is being discharged should be fully known and recognised, and their needs met. We had a good discussion about that and we know that that does not happen, but the pressure on young carers is particularly acute. As part of that discussion last week, I almost intervened on the Minister to ask that when we are considering carers more generally, we highlight young carers separately. A hospital needs to know and understand that the person going back home will be in the charge of a young carer, and the local authority needs to make sure that a needs assessment is conducted.

The new clause suggests that should happen before the patient is discharged. Clearly, the Bill is instigating a new process, which will look at post-discharge. We had a good debate about that. As my hon. Friend the Member for Nottingham North said from the Front Bench, doing that assessment differently may be better in the long run—we do not know. In particular, when it comes to young carers taking up that role, it is even more acute that it is recognised in the new arrangements.

I will not move the new clause to a vote, but I would like the Minister to be cognisant of young carers and assure us that these needs will be highlighted to hospital trusts and local authorities in the discharge planning process.

--- Later in debate ---

[Dr Whitford]

I accept the Minister’s reassurance that they will finally look at correcting this anomaly; I hope that he will take that forward. It is something that we will be looking for. I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 66

Support provided by the NHS to populations at risk of malnutrition

“(1) Each integrated care board must—

(a) assess, or make arrangements for the assessment of, the need for support for patients and/or populations at risk of malnutrition, including social and clinical/disease related malnutrition, using their services;

(b) prepare and publish a strategy for the provision of such support in its area;

(c) monitor and evaluate the effectiveness of the strategy; and

(d) designate a malnutrition lead.

(2) An integrated care board that publishes a strategy under this section must, in carrying out its functions, give effect to the strategy.

(3) Before publishing a strategy under this section, an integrated care board must consult—

(a) any local authority for an area within the relevant Integrated care board’s area; and

(b) such other persons as the relevant local authority considers appropriate.

(4) For the purposes of subsection (3), ‘local authority’ means—

(a) a county council or district council in England; or

(b) a London borough council.

(5) An integrated care board that publishes a strategy under this section—

(a) must keep the strategy under review;

(b) may alter or replace the strategy; and

(c) must publish any altered or replacement strategy.

(6) The Secretary of State may by regulations make provision about the preparation and publication of strategies under this section.

(7) The power to make regulations under subsection (6) may, in particular, be exercised to make provision about—

(a) the procedure to be followed by an integrated care board in preparing a strategy;

(b) matters to which an integrated care board must have regard in preparing a strategy;

(c) how an integrated care board must publish a strategy;

(d) the date by which an integrated care board must first publish a strategy; and

(e) the frequency with which an integrated care board must review its strategy or any effect of the strategy on the provision of other provision in its area.

(8) Before making regulations under this section, the Secretary of State must consult—

(a) all integrated care boards; and

(b) such other persons as the Secretary of State considers appropriate.” —(Alex Norris.)

This new clause would require integrated care boards to publish a strategy for the provision of support for patients and/or populations at particular risk of malnutrition using their services, and designate a malnutrition lead.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

This new clause would put responsibility on integrated care boards to take the lead on tackling malnutrition in their community. We spoke about malnutrition in the context of hospital food standards, and we were not able to move the Minister to extend those hospital food standards to other care settings. I thought that was a shame, and I hope the Government will continue to look at the issue. I want to broaden the conversation on malnutrition to try, via another way, to improve the standing of our communities.

Malnutrition is a serious condition that occurs when a person does not get the energy or vitamins that their body requires to function properly. It affects at least 3 million people every year, and it costs the health and social care system £23.5 billion each year. The condition is particularly common amongst certain groups. Those groups are: older people; hospital patients; people in mental health units and care homes; people living in sheltered housing; and those living with chronic diseases, such as cancer. Malnutrition can seriously threaten patients’ health. Hospitalised malnourished patients are three times more at risk of infection than the well-nourished, while hospital patients at high risk of malnutrition are 12 times more likely to die early than those at no risk. It is a very significant issue. Unfortunately, the figures are not moving in the right direction. The number of adults being admitted to hospital with malnutrition has more than doubled in the last decade—that is the bill for austerity. The evidence is clear that malnutrition impacts a wide range of people in different health settings; again, those are hospitals, mental health units, care homes and sheltered housing. It has a knock-on effect on other conditions.

Earlier this year, the media reported the death of a young disabled woman after a routine operation. Her death was partially caused by malnutrition, and the coroner said there had been a gross failure of care in managing her nutrition. A July 2021 report on malnutrition called it a widespread yet historically overlooked and undertreated issue in the NHS and social care, and attributed that to two factors that block progress—a lack of understanding, and a lack of systematic leadership. The new clause seeks to address that at a local level, which is why we think it is a good one.

The tragic case that I have mentioned shows how important it is to have a clear strategy to tackle malnutrition, to have designated leads and to have targets and co-ordinated policy. The Government say that integrated care boards are about ensuring proper integration between health staff and community services, and this is a really good example of a way in which that could be done. I am keen to hear the Minister’s assessment of the new clause, which should be included in the Bill. We have a significant issue that we are not addressing and that is getting worse, so what are we going to do differently?

[Edward Argar]

We recognise and know that malnutrition can be a significant problem that can be both a cause and a consequence of ill health. We remain committed to improving the NHS and public health systems, which is helping to improve health and secure early diagnosis of major diseases, tackling some of the root causes of malnutrition. That is backed by the development of the outcomes frameworks covering public health, the NHS and social care, and the development of specific disease outcome strategies.

Individuals, carers and professionals all have a role to play in tackling malnutrition, and there are tools and guidance in place through a range of organisations to help health and social care professionals identify and treat the problem of malnutrition, and to access appropriate training. I note that e-learning modules are currently in place through the Royal College of General Practitioners and the managing adult malnutrition in the community pathway, which was set up by a multidisciplinary group and is widely endorsed by professional bodies aimed at healthcare professionals.

I hope I speak for the whole Committee when I say that we all agree that the NHS can play a vital role in protecting vulnerable people. As part of that, it should have strategies and processes in place for supporting patients and vulnerable people in the community who are at risk of malnutrition. I hope I can reassure the Committee that placing in the Bill a formal duty on ICBs to develop a separate strategy is not strictly necessary, as there is a range of ongoing activity across health and care.

As we have previously discussed, there are already significant existing duties, and duties proposed in the Bill, to prepare plans, including joint local health and wellbeing strategies made at a local authority level by health and wellbeing boards, the integrated care strategy that is to be developed by the integrated care partnership, and the forward plan that is to be developed by the integrated care board. All those plans should be informed by local joint strategic needs assessments, or JSNAs. All the strategies can, where appropriate, consider malnutrition and populations at risk of malnutrition. We have previously debated the range of guidance available to inform thinking on both JSNAs and strategic plans, and we will of course work with NHS England to consider whether it is necessary to include specific references to malnutrition in the guidance.

Should the Bill pass into statute, we expect clinical commissioning groups and ICBs to consider the needs of patients and vulnerable people in their communities, including people who may be at risk of malnutrition. That includes working across health and social care partners to undertake needs assessments on malnutrition, and developing and implementing a work plan to maintain high standards of nutrition through integrated pathways of care. NHSEI’s enhanced health in care homes implementation framework sets out best practice guidance for primary care networks and others in relation to hydration and nutritional support for care home residents. The framework supports the implementation of minimum standards in relation to enhanced health in care homes in the Network Contract Directed Enhanced Service for 2020-21.

The malnutrition task force has also published a series of guides offering expert advice on the prevention of and early intervention in malnutrition in later life, which will support health and care bodies. Alongside that, we have published an independent review of hospital food, which made recommendations for addressing malnutrition in hospitals, and a review of what works in supporting older people in the community to maintain a healthy diet. This “what works” review included a range of examples of good practice at local authority level that others can learn from, and we have provided in the Bill for powers to impose requirements on hospital food standards.

We are helping to raise awareness of malnutrition among individuals and carers through the nhs.uk website, and through the NICE quality standard on malnutrition, which gives a clear and authoritative statement of a quality service. There are ongoing inspection requirements, including for unannounced inspections of health and care settings by the Care Quality Commission, which will continue to ensure expected standards are met.

The new clause would place a requirement on ICBs to have a malnutrition lead. The Bill intentionally allows for flexibility in the make-up of ICBs above the minimum membership requirements that we have previously debated in Committee. They could, if they wished, include condition-specific officers, but we do not want to bind their hands by specifying that they must. That once again returns to the permissive versus prescriptive thread that has run through many of our debates.

However, I do see a huge opportunity for ICPs to consider how best to improve services for people at risk of malnutrition through better partnership and joint working and planning of services, given the complementary services that the NHS and local authorities offer in this context. The new Office for Health Improvement and Disparities is committed to improving the diet of the population and supporting people to maintain a healthy weight.

I hope I have given the Committee some reassurance that we are taking this issue extremely seriously and are committed to enabling the NHS and the wider health and care system to effectively tackle malnutrition.

[Alex Norris]

I was a little surprised to hear the Minister defend the status quo. The state of play in this country is not good enough and is getting worse, so I dare say that more of the same will beget more of the same. The Minister said that the new clause was not necessary because of the range of ongoing activity, but I reiterate that what is happening is not sufficient and is not addressing this really important issue.

The two areas for development that were offered were local prioritisation through integrated care strategies and the Office for Health Improvement and Disparities. They are obviously relatively new actors in this space, so it is probably right that we give them time to see whether, as the Minister says, they will prioritise this, choose to make it a top-rated issue and do something about it. I am very sceptical of that, and I suspect that we will be back at this sooner rather than later. However, in the meantime, I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 67

Review of the capacity of the dental laboratory sector

“The Secretary of State must within six months of the passage of this Act publish a report assessing the capacity of the dental laboratory sector in the UK to meet the needs of patients.”—(Alex Norris.)

This new clause would require the Secretary of State to review the capacity of the UK’s dental laboratory sector.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

[The Chair]

With this it will be convenient to discuss new clause 68—Access to NHS dentistry—

“The Secretary of State must within one year of the passage of this Act publish a statement setting out what measures the Government is taking to ensure universal access to NHS dentistry.”

This new clause would require the Secretary of State to publish a statement of what measures it is taking to ensure universal access to NHS dentistry.

[Alex Norris]

The two new clauses refer to two linked but distinct sectors of the heath service—dental laboratories and dentistry. In each case, we are seeking for the Secretary of State to publish a report about the health of these important sectors.

On new clause 67, the dental laboratory industry manufactures dental appliances to assist in the provision of oral care, such as crowns, bridges and dentures. The British dental laboratory industry plays an important part in the wider oral health landscape, and it is vital for patients, dentists and other registered dental care professionals. This is an unheralded industry, but it touches all our constituencies, and enables our constituents to live without pain. It also provides skilled work in an economy that has too little of it. It is based in communities all over the country, not concentrated in big cities or in London and the south-east. In many ways, it is a towns industry in a country that desperately needs more towns industries.

However, the industry is struggling. It was struggling prior to the pandemic, but it has particularly struggled during it. In the early stages and indeed even today, dentists have rightly—we supported this—been paid full contract for reduced output to reflect the challenging circumstances in which they are operating, but there has never been an obligation to pay this forward to their suppliers. Whereas we might normally expect dental labs to account for 6% to 7% of a dentist’s outgoing, as output has fallen so has that outgoing, so the sector has suffered, but dental labs have needed to stay open to meet need, so they have not been able to completely avail themselves of support.

The messaging around dentistry at a local and national level has also had knock-on impacts for dental laboratories trying to make insurance claims for business disruption, because there has been a misunderstanding, shall we say, about whether they are operating, and how they are operating or not operating.

--- Later in debate ---

[Justin Madders]

As my fellow shadow Minister quite rightly points out, this is a huge issue for most constituency MPs. I am not surprised to hear what he said about this being the No.1 complaint to Healthwatch, because behind GP access, dental access is now a huge issue. Before the pandemic, dental services in the Cheshire area were contracted to attend to 55% of the local population’s dental health needs. Clearly, that is insufficient, but the challenges of the pandemic have only made matters worse. I encourage my hon. Friend to continue to raise this very important issue.

[Alex Norris]

I am grateful for that intervention. It is sobering to hear that 55% was what we started with; we know that it will be less than that now. That rather picks away at the idea of a universal healthcare service.

To finish where I was going with my previous point, if I am wrong about where recovery funding for the NHS is going, and there is to be investment in dentistry, I hope that the Minister will correct me. I would be delighted if that was the case, because the BDA is warning—again, this is something that we will have picked up on in our constituencies—that morale among NHS dentists is at an all-time low. Almost 1,000 dentists in England have stopped providing NHS services in the last financial year. There was the failed contract—I know there is enthusiasm for contract reform in the Department and we will support the Department on that, but we are running out of time to have anything ready for April. In fact, we are probably already too late in that regard. The shambles of the negotiations before Christmas last year that led to the breakdown and the imposition of targets really whittled away at good will and caused a lot of upset.

Almost half of NHS dentists are saying that, unless things change, they intend to hand back their contracts or reduce their NHS commitment. This exodus of dentists from the NHS will have a disastrous and lasting impact on our ability to access NHS dentistry. If 55% is the summit of our ambition, goodness me, where will we go from there? The British Dental Association talks about the last-chance saloon; it is not hyperbole to say that we will not have NHS dentistry in the medium term if we do not have a course change.

More and more people are being pushed into the private sector. That creates market forces that mean that it is almost a self-fulfilling prophecy that dentists—both new ones entering the profession and those who have come to the end of their tether with their NHS contract—go into the private sector. We are seeing significant growth in that space as people living in pain seek drastic action. We will see more pushed on to dental insurance if people do not want to be worried about their finances. That is what privatisation looks like. We will not have NHS dentistry in the medium term unless we do something about this issue—that is the wrong way forward.

New clause 68 makes a very modest ask; it asks the Secretary of State to do what any Secretary of State should want to do: commit to universal access to NHS dentistry and say how it will practically be achieved. At the moment, we have a yawning gap. In that lack of leadership, we will see the drip, drip, drip of the loss of NHS dentistry, until we no longer have it.

[Dr Whitford]

I rise to support new clause 68, which is linked to new clause 67. We are aware of the impact of the pandemic, particularly on dentistry. Using a drill on someone’s teeth generates aerosols in their mouth, and that would vastly increase the risk of spreading covid to the dental staff, or to any patient who entered the space soon afterwards. Despite that impact, there has not been significant funding from the UK Government for the dental industry in England to fund the establishment of ventilation and air purification systems. The Scottish Government have committed £5 million specifically for this. As the hon. Member for Nottingham North highlighted, the pandemic impact comes on top of an underlying issue, the core of which is the 2006 dental contract in England and Wales, which breaks provision down into units of dental activity. It does not reward preventive dentistry. It does not reward any practice for taking on someone who already has dental issues, because it will not be properly funded for that.

Out of that comes the failure to focus on child dental health and making sure that this generation of young children grow up with good dental health. Scotland set up Childsmile in 2007, and Wales set up Designed to Smile in 2011. There is plenty of data from both of these programmes to show that providing free dental treatment to children—along with supported tooth brushing at school, fluoride coating and so on—can decrease caries found in children in primary school and at the beginning of secondary school.

Poor dental health has a big impact on general health and self-confidence, yet we hear repeated reports of families and children struggling to access an NHS practice. In the last five years, NHS practice numbers in England have dropped by over 1,250. BDA surveys suggest that almost half of remaining NHS practices are planning to reduce their NHS commitment over the next 12 to 24 months. There was a promise that the contract would be changed by next April, and 100 practices have been trialling a new method of contract. According to the BDA, it has been warned of a return to using units of dental activity from next April. This would be an enormous missed opportunity to improve NHS dental access for everyone, and particularly to take the further step of ensuring that every child in England does not just have access to a dental practice, but is involved, as they grow up, in a programme promoting good dental health.

--- Later in debate ---

[Edward Argar]

I am very touched by her medical concern for my welfare.

In light of the reduction in activity within dentistry due to the pandemic, dental practices have been asked to deliver as much care as possible, with their first priorities being urgent care, care for vulnerable groups and for children, and then delayed planned care. I put on the record my gratitude to the profession for its hard work and efforts during this time, and I am pleased to note that the levels of urgent care being delivered have now returned to pre-pandemic levels, because of the over 700 urgent care centres established in practices to improve access for people during the pandemic. Throughout the pandemic, we have worked closely with NHS England and NHS Improvement to consider the level of NHS dentistry that can be delivered safely. Activity thresholds for full renumeration are based on data showing what is achievable while maintaining compliance with infection prevention and control measures.

The pandemic has reinforced the fact that transformation in NHS dentistry is essential. As has been alluded to, NHSEI is leading ongoing work on reforming the current dental system, working with a wide range of stakeholders and system partners. We acknowledge that, even before the pandemic and the imposition of limitations that it necessitated, access to NHS dentistry was sometimes a challenge in some areas and for some people. Putting that right will require action to both reform contractual arrangements and ensure that there are trained and qualified dental teams providing NHS services throughout the country.

Since the announcement in March that NHSEI is leading on the next stage of dental system reform, it has continued to work closely with system partners and stakeholders, including the British Dental Association in particular. The NHSEI dental system reform will deliver against a number of fundamental aims, including delivering improved health outcomes, an increased focus on preventive dental work, affordability for patients, and recognising that changes need to be supported by the profession. Making the NHS dental contract more attractive to the profession is a key part of helping with vital recruitment and retention. I know that will be particularly welcome to hon. Members from rural and coastal areas, as it has been highlighted that there is a particular challenge in some of those communities.

A key objective of this work is to improve patient access to NHS care, with a specific focus on addressing inequalities. We will set out our proposals in that area next year, in addition to the provisions in this Bill that will allow the Secretary of State to expand water fluoridation schemes. In addition, Health Education England’s “Advancing Dental Care” programme will, over the next four years, deliver its blueprint for change to reform education and training, develop skills, enable modernised flexible working, and widen access and participation among the workforce.

Together, we believe these measures will address the key challenges that impede the delivery of NHS dentistry, and improve patient access to NHS care. The Government will carry on with this essential work, and will continue co-operating with HEE and external stakeholders on this important issue. For that reason, I ask—possibly in vain—that the hon. Member for Nottingham North considers withdrawing the new clause.

[Alex Norris]

I am grateful to colleagues for their contributions. I am particularly glad that the hon. Member for Central Ayrshire brought up units of dental activity, which are a Treasury way of understanding activity, not a public health way of understanding oral health. Although they are effective for setting balanced budgets on an annual basis, they are really bad for saving money—in fact, they have cost money. There is broad consensus that UDAs are long out of date, and that after 15 years, it is time to move away from them.

Dealing with new clause 68 first, I was glad to hear the Minister at least suggest that this is an active process, because it was the first sign I have seen that the move away was not just a conceptual one. On that basis, I will not press the new clause to a Division, because we will not prejudge that process. However, I gently say that we really need to get on with this, because lots of dentists are waiting on the outcome of that process before making their judgment as to whether or not NHS dentistry is in their future. I was also glad to hear the Minister acknowledge that the system was not good enough before the pandemic. In response, I would say that removing a third of the real-terms funding was perhaps a significant reason why it was not very good anymore, and in future the answer may lie in tackling that point.

Turning to new clause 67, I was of course glad to hear the Minister say that this issue is being taken seriously. However, I was not clear on what “taken seriously” means beyond the existing support there is for businesses generally, not least because dentists have operated in this half space of still being open but not having the fullest demand on their order books, which has often meant that they have fallen between stools. However, I think the offer of that meeting is better than the new clause and, on that basis, I will pursue the route of that kind offer. I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 69

National lead for policy related to allergies

“Within 6 months of the passage of this Act the Secretary of State must direct NHS England to designate a national lead for policy related to allergies.”—(Alex Norris.)

This new clause brings in a requirement for the Secretary of State to ensure the appointment of a NHS England allergy lead.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

New clause 69 is very important indeed. It requires the Secretary of State to direct NHS England to appoint a tsar to lead on policy related to allergies.

In 2016, 15-year-old Natasha Ednan-Laperouse tragically lost her life after suffering an allergic reaction to a Pret A Manger baguette. Since then, her parents have campaigned tirelessly to ensure that her death was not in vain and to stop other parents and loved ones having to suffer as they are suffering. They set up the Natasha Allergy Research Foundation and their campaigning has already successfully led to Natasha’s law, which was implemented just last month and requires food retailers to display full ingredient and allergen labelling on foods made on premises and prepacked for direct sale. That is a tremendous achievement, and it will make a significant difference to lots of people. I have met the Ednan-Laperouse family, with their MP, my hon. Friend the Member for Hammersmith (Andy Slaughter); they are inspiring people and tremendous campaigners. The new clause is very much in the spirit of their latest campaign—I certainly would not bet against them.

The World Health Organisation has described allergic disease as a “modern epidemic”, while Allergy UK estimates that up to 21 million people in the UK are affected by allergies. Allergic disorders can have a detrimental impact on patients’ quality of life, as they not only have the obvious health effects, but can mean that social interactions that others take for granted—such as eating out, or even going to work—are a major health risk. Allergies can be complex: patients can suffer from several disorders at the same time, each triggered by different allergies.

In the 20 years to 2012, hospital admissions for anaphylaxis rose by 615%. Despite that, allergies are not particularly high up the political agenda for conversation and there is a perception of poor management across the NHS due to a lack of training and expertise. At the root of that is the fact that we have a very small number of consultants in adult or paediatric allergy and the fact that GPs receive basically no training in allergy.

Following the inquest into the death of Shanté Turay-Thomas—another tragic teenage death—the coroner highlighted the lack of a national allergy lead in her prevention of future death report, which was sent to the Department of Health and Social Care. I think today is a chance to make good on that, and I would be very interested to hear what the Minister has to say on those suggestions. Natasha’s foundation, with the support of Shanté’s mother, subsequently made the call for an allergy tsar.

Two weeks ago, the all-party parliamentary group on allergy, in conjunction with the National Allergy Strategy Group, launched its report, “Meeting the challenges of the National Allergy Crisis”. The report

“calls for an influential lead for allergy to be appointed who can implement a new national strategy to help the millions of people”

suffering. There is a real coming together across our communities of people in this space calling for this measure, and this the moment to do it.

Otherwise, as I have suggested, NHS allergy services will continue to get little attention, little prominence and little investment. Care is patchy and we know that people deserve much better support. An allergy tsar would act as a public champion for those with allergies, helping to deliver a national plan to join up GP and hospital services so that patients have a consistent and coherent NHS care pathway, and helping to promote the training of more specialist allergy doctors, consultants and GPs. It would make a difference to millions of people. I hope that the Minister will look upon the new clause favourably and give the answer that millions of people are waiting for.

[Edward Argar]

As the shadow Minister set out, the new clause would place a statutory responsibility on the Secretary of State, requiring him or her to direct NHS England to appoint an allergy lead. The shadow Minister rightly highlighted that tragic case that demonstrated to the country the issues and challenges in this space. I entirely sympathise with the intent of the hon. Gentleman, but I hope I can provide him with some reassurance that the amendment is not necessary, because NHSE is already able to appoint an allergy lead, or allergy tsar—call it what you will.

There is no specific national clinical director or specialty adviser for routine allergy services, but I am advised that NHS England and NHS Improvement keep their clinical leadership, including the national clinical director and national specialty adviser roles, under review to ensure alignment with the strategic priorities of the NHS and need. I am sure that NHSE will reflect carefully on the points made by the hon. Gentleman, and I will undertake to acquire a copy of the Hansard to pass on to NHS England and request that it considers the points he made in this context.

I also recognise that, more broadly, it is vital that NHS England and commissioners receive appropriate clinical advice in this area. That is currently provided by the clinical reference group for specialised immunology and allergy services. The CRG covers specialised treatment of certain immunological and allergic conditions. The allergic conditions include severe, complex and/or rare sub-groups. People with allergies continue to be supported through locally commissioned NHS services but, to support patients with more complex conditions, NHSE also directly commissions some specialist services. To support the implementation of coherent care pathways, NICE has also published guidance on a range of allergy conditions, including food allergy in under-19s, anaphylaxis and drug allergy.

We therefore do not believe that the new clause needs to be included in the Bill. Notwithstanding whether the hon. Gentleman decides to press it to a Division, I undertake to ensure that his comments and the case he makes for the role are passed on directly to NHS England. NHSE already has the power, should it wish to exercise it, to put such a person in post.

[Alex Norris]

I am grateful for that offer. I hope that when NHS England has a chance to consider what has been discussed in Committee, that will generate an offer to meet campaigners to understand what they are after and, we hope, to move positively on it. Beyond that, I am afraid that the Minister’s answer was too much in defence of a status quo that does not work for too many people for me to accept it. In the spirit of elevating the matter up the political agenda and creating that blinking light on someone’s dashboard to generate action, I will press the new clause to a vote.

Question put, That the clause be read a Second time.

Endometriosis and Polycystic Ovary Syndrome

Alex Norris Excerpts

Monday 1st November 2021 Westminster Hall

[Alex Norris (Nottingham North) (Lab/Co-op)]

Mr Mundell, you talked about doing justice to Sir David’s memory. Like possibly everybody in this place, my friendship with David was one that was funny and light. I loved how serious and passionate he was about the issues that he cared about, so I think we have done justice to his memory today. Everybody can be proud of that, none more so than my hon. Friend the Member for Coventry North West (Taiwo Owatemi), who, as she said, could have talked dispassionately about this issue, but it was much better for her not having done so.

Similarly, I always have pride and admiration for anybody who goes down the petitions route to secure a debate in this place, because it is very hard to do. The fact that they have been successful demonstrates the strength of feeling. If that petition came from a place of frustration that these two conditions, endometriosis and polycystic ovary syndrome, lack public prominence, I hope this debate is a part of tackling that and that they take pride in that.

There were too many contributions to cover individually, but in aggregate colleagues have written for the Minister a manifesto for where to go next. There were common themes—a desire for better diagnosis and better understanding in primary care—and strong themes around the desire for more research and better support at work or through the welfare system. I hope the Minister will take from that four very concrete things that can be done quickly and can be focused on.

There were contributions that I did not want to miss, particularly from my hon. Friends the Member for Streatham (Bell Ribeiro-Addy) and for Worsley and Eccles South (Barbara Keeley), and from the hon. Member for East Renfrewshire (Kirsten Oswald), who talked about their personal experiences. I hope that the many people watching this, either in the Public Gallery or online, who are themselves experiencing these conditions, took some comfort from hearing about the lives of their representatives and how brave and willing they are to tell their own stories, which really enriched the debate.

My hon. Friend the Member for Kingston upon Hull West and Hessle (Emma Hardy) and the hon. Member for Livingston (Hannah Bardell) are the new co-chairs of the all-party group on endometriosis. We can have a lot of confidence in their leadership of that important parliamentary group. They brought hope in their contributions, so that gives us optimism for the future.

Before I make a couple of points of my own, I want to reflect on the points made by the hon. Member for Thurrock (Jackie Doyle-Price) about the gendering of healthcare in this country. Once again we saw great parallels from the debates following the Cumberlege review and the same messages coming back. To be clear, Mr Mundell, there is a one in 10 chance that either of us might present to our GP with erectile dysfunction. I know for certain that the GP would not say to either of us to come back when we wanted to have a child, and they certainly would not suggest removing the offending organ. Just as we would not tolerate that attitude, we should not tolerate it for anybody in this country.

Turning to endometriosis, Sarah Harris is a 23-year-old freelance journalist from my city of Nottingham, who has written about her experience. I will read a couple of paragraphs because they explain powerfully about life with endometriosis. She wrote:

“It’s hard to remember a time in my life where I wasn’t in pain. Memories of my youth are intertwined with flashbacks; hiding in toilets as blood soaked through my primary school uniform, curled up on the floor of the nurse’s office during secondary school whilst clenching my stomach in agony, skipping lectures in the first few weeks of university as I changed my sanitary pad for the third time that hour.

For a long time, I thought this life was normal. After all, from the age of 12 onwards doctors had been telling me that this was all just a ‘part of being a girl’ and I had to ‘deal with it’. By the time I realised this life was in fact far from normal, it was too late.”

Sarah’s story is not unusual. We have heard that the average diagnosis takes about eight years. Last year’s parliamentary inquiry found that nearly 60% of those with symptoms who were later diagnosed with endometriosis had visited the GP more than 10 times; one in five had had 10 or more hospital appointments; more than half had gone to accident and emergency, and one in four had gone more than three times—all of that happening before diagnosis. That is a real system failure. To put it in pounds and pence—if we really have to—that is more than £8 billion a year, through treatment, healthcare and the impact at work. It is a very significant challenge which behoves action.

Similarly, PCOS affects one in 10 women. We know that while there is no cure, there is treatment. PCOS can exacerbate long-term health conditions such as cancer and type 2 diabetes and, similarly to endometriosis, diagnosis can take many years. There is evidence of a genetic link and, as my hon. Friend the Member for Coventry North West said, a higher prevalence in certain ethnic groups, such as black and south Asian women. Again, it is something that Parliament ought to get a grip on. Those significant challenges are happening at a population level. As I said, the common theme is that it happens to women and those assigned female at birth.

We are currently debating the Health and Care Bill in Committee, which resumes for the final day tomorrow. We have discussed issues such as women’s health, reproductive health and the Cumberlege report on multiple occasions. There is nothing in the Bill on those issues and, I am sad to say, our amendments have not been accepted. What I have heard consistently from Ministers is that the women’s health strategy is coming and that action will be taken through that. I hope that the Minister in closing will make that commitment herself, because an awful lot of people are putting an awful lot of stock in that strategy.

I particularly hope that we will hear a commitment on research, because women’s health is under-researched. The “UK Health Research Analysis 2018” report showed that only 2.1% of publicly funded research in the UK was on reproductive and menstrual health, which is less than half of what it was in 2014. Of the more than 8,000 research projects funded by the National Institute for Health Research—an outstanding body—10 were on endometriosis and one was on PCOS. There is clearly significant space to do much better on research in this country. Only last year, the Australian Government committed $9.5 million to that research—we need that sort of ambition in this country as well.

I want to leave the Minister plenty of time to come back on all the important points that have been raised, so I conclude by saying that I think colleagues have written a really good manifesto for her. We want better diagnosis, better understanding in primary care, more research and better support at work or through the welfare system.

Health and Care Bill (Twenty First sitting)

Alex Norris Excerpts

Committee stage
Thursday 28th October 2021 Public Bill Committees

Brought up, and read the First time.

[Alex Norris (Nottingham North) (Lab/Co-op)]

I beg to move, That the clause be read a Second time.

It is a pleasure to resume our consideration with you in the Chair, Ms Elliott. The new clause is in my name and those of my colleagues. If we think about the pandemic and the last 18 months, we will have various views on all sorts of things that have gone on during that period, but I think that one thing that we would be of one mind on is how well our nation’s directors of public health have performed in this crisis. They have been incredible, pulling together the local response and bringing to bear their unique combination of training, relationships and local soft power in order to ensure that the local approaches to dealing with the pandemic in aid of the community have been strong ones. I think we would all say that they have done absolutely superbly.

The new clause seeks to codify a little more formally the place of directors of public health in the system. As we are authoring a new system in the Bill, this is no bad time to do that. The purpose of the new clause is to clarify the roles, powers and duties of directors of public health and to put them on a statutory footing. Whatever structures DPHs sit within, their major role—the reason why as a country we need them and why we invest in them as we do—is that they act as an independent advocate for the health of the population, for system leadership and for the improvement of the system for the population. They are already responsible within their area for a broad range of things, such as measurable health improvement, health protection, public health input, planning, commissioning, reducing inequalities and more. There is a strong reason to put them on a statutory footing. They of course provide an independent advisory function for a wide range of organisations, including the NHS. My local DPH is very good indeed. She often reminds colleagues that she is the system’s DPH rather than just the local authority’s. She may well be hosted by the local authority, but her remit goes much broader, and that is a very good thing. Putting DPHs on a statutory footing would recognise the system leadership role that they have.

The new clause would use a corporation sole model to ensure that directors of public health have scope for independent action; it would ensure that special arrangements are made for them, as officers of the Crown, to bring certain things to the attention of the Attorney General and the chief medical officer, and to ensure public health representation on NHS managing, regulating or commissioning bodies where necessary; and it would guarantee their professional independence in these wider functions. In the vast majority of cases across the country, most of these functions and roles are operating very well indeed, but the new clause would give statutory underpinning to that.

Together, these changes would allow DPHs to have influence across the entire place that they work for and across all policy areas, including budgetary and allocative decisions, and ensure that they have a chance to play their part across all decisions being made in the local community that impact on public health. This proposal would hardwire links between DPHs and the NHS public health workforce who enact public health policy. For place-based officials, having strong links with local and regional NHS employees is not only a benefit but a necessity. It would help to strengthen our response to health inequalities and hence the prevention of ill health—we have spoken at length about that during these proceedings—as well as enhancing relationships for emergencies, which we have seen in recent months.

Where this is done best, it is a strong model. I know that some directors of public health have consultants within their local NHS trust. That is something that the Association of Directors of Public Health is very keen on. If the Bill and the direction of travel are about an integrated system, those kinds of integrators are a very good model of doing that.

These are critical roles. We have seen that in challenging times, but in more general times, as we push on in order to have a healthcare system that is more preventive, that closes inequality gaps and which delivers excellent services to our population, directors of public health will be really key players in it, so I hope that this attempt to put them on a slightly stronger and more consistent footing will be welcome.

[The Minister for Health (Edward Argar)]

It is a pleasure to see you in the Chair once again, Ms Elliott.

My understanding, in the light of what the shadow Minister has said, is that one of the underlying aims of the new clause is to ensure that the public’s health is at the fore as we reform the health and care system. I have the utmost sympathy with that an aim

The Government recognise the importance of a robust public health system that works to improve the health and wellbeing of the nation and to prevent disease. That is why we have taken decisive steps to reshape our national public health bodies so that we are well equipped to face future challenges. Furthermore, we agree that directors of public health and their teams should have a crucial role at the heart of the new system.

The shadow Minister is absolutely right to say that although directors of public health are hosted by local authorities, they represent the whole system, and we owe them a debt of gratitude. In our past lives, he and I would have worked with DPHs in our local authority contexts, and of course, as Members of Parliament, we have all seen what our local DPHs have had to do over the past year and a half. I suspect that Members who did not know their local DPH have probably got to know them and their work in the community a lot better, which is no bad thing.

This fits naturally with the strategic emphasis on population health that we expect of integrated care systems. Both the Department of Health and Social Care and NHS England have set out in published policy and guidance documents our expectation of directors of public health having an “official role” in integrated care systems. Officials in the Department are working closely with the Association of Directors of Public Health and others to help describe further the place of these roles, the outcomes that we hope collectively to achieve, and the ways in which they can best add value to the system’s impact on health overall.

Although we entirely understand the motivation behind the new clause, I am not sure that it is strictly necessary. It seeks to clarify the roles, powers and duties of DPHs, but their roles and responsibilities are already clearly and accurately set out in legislation and current guidance. The requirement for the recruitment to the role of director of public health, for example, is already clear on professional qualifications, and the registration and regulation requirements are clearly laid out. The new clause may have the effect of reducing the flexibility of the post, although I am sure that the shadow Minister would say that that concern is unfounded.

Furthermore, the current system already provides independence and influence for directors of public health, and that is strengthened by several provisions in the Bill, which includes, for instance, a duty on ICBs to seek advice from persons with the appropriate expertise on prevention and public health, including directors of public health, complementing the existing duty, in the section 6C regulations of the National Health Service Act 2006, for local authorities to provide the NHS with public health advice.

Additionally, we do not believe it necessary to make directors of public health officers of the NHS, as the Bill already provides opportunities for DPHs to link into and influence NHS bodies in their current guise. Integrated care partnerships, for instance, must develop an integrated care strategy to which integrated care boards must have regard in drawing up their commissioning plans. The intended result is to create a plan to meet the health—including public health—and social care needs of the population within their defined geography. That will provide directors of public health with the opportunity to influence NHS commissioning plans to meet wider public health aims.

It is also possible that the new clause would create a number of undesirable consequences—I suspect that the shadow Minister will allay some of those fears in his response. Rather than bringing clarity, the new clause could create confusion and complexity in a system that is already functioning effectively with a clear understanding of the role and how it operates.

The new clause would put a host of prescriptive new requirements on DPHs, including a requirement for them to be officers of the NHS, NHS consultants in public health, and officers of the Crown, while retaining independence of thought and action.

While we certainly understand the motivation of wanting to knit together the system through an individual post, that approach would add a layer of complexity. I believe that it would be challenging for an individual holding that office to seek to balance those complex responsibilities, accountabilities and potentially competing priorities within various organisations. That would also complicate the lines of accountability

My concern is that the new clause is overly prescriptive about the status and nature of the role, which would go against the overall aims of the Bill in terms of permissiveness. Although we hope and expect that directors of public health will act as a nexus for bringing coherence to the local system’s focus on population health, we are not convinced that this level of prescription over permissiveness is appropriate. That reflects a thread of the debate throughout the passage of the legislation on where the appropriate balance should be struck.

Proposed new paragraphs (e) and (h) would weaken the ties that directors of public health have with local authorities. Since the 2012 reforms, there has been widespread consensus that local authorities are best equipped to deal with a wider range of public health matters for their population’s needs. In that context, I pay tribute to local authorities for their role in tackling the pandemic, including those in elected roles. If I recall correctly, the wife and partner of the shadow Minister, the hon. Member for Ellesmere Port and Neston, is active as an elected councillor in a local authority. Many Members of this House will have served in that role, too, and will recognise what local authority councillors and officers do in that space.

From their home in local government, DPHs have been able to maintain an independent mindset while playing a critical role in improving and protecting the public’s health. Although it may well evolve in future, that system is working, and we have a strong and solid base that is understood by all system players. I therefore encourage the shadow Minister to continue to work with me and others to make that system work, rather than seeking to press the new clause to a Division.

[Alex Norris]

I certainly did not intend to add complexity; I was hoping for clarity and consistency. Nevertheless, as the Minister says, those roles are currently functioning effectively, so I will not divide the Committee.

I would say to the Minister and his colleagues, however, that we need a real watching brief on this matter, because assuming that the Bill continues its onward journey and establishes those ICS footprints, there will be a range of different outcomes and organisational cultures. The stronger systems will be those in which the DPHs are at the heart of insight and decision making, and the reverse will be a defining characteristic in systems that are not as good. I certainly hope that we consider the Care Quality Commission reviews that were included in an earlier new clause, and any sector-led improvement, as well as the work those systems do to reflect on what they do and do not do well.

One of the criteria for both streams of improvement ought to be what the DPH does, how central they are, and how sighted they are on decision making. As I have said, in good systems that will be good, and in weak systems it will be weak. Those criteria would be a bellwether of how good the local ICS footprint is. I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 45

Duty on integrated care boards to have regard to net zero commitment

“(1) The National Health Service Act 2006 is amended as follows.

(2) After section 14Z43 (inserted by section 19 of this Act) insert—

“14Z43  Duty to have regard to net zero commitment 

When procuring or commissioning goods and services on behalf of the NHS, integrated care boards must have regard to NHS England’s commitment to reach net zero by 2040.””—(Justin Madders.)

This new clause would place a duty on integrated care boards to have regard to NHS England’s commitment to reach net zero by 2040.

Brought up, and read the First time.

[Justin Madders (Ellesmere Port and Neston) (Lab)]

I beg to move, That the clause be read a Second time.

It is a pleasure to see you in the Chair, Ms Elliott. I will be brief in speaking to the new clause. What we are seeking to achieve is pretty clear: for integrated care boards procuring or commissioning goods and services on behalf of the NHS to have regard to NHS England’s commitment to reaching net zero by 2040.

We can assume that the Government fully support the commitment made by NHS England. We were all transfixed by the goings-on in Committee yesterday, so we may have missed the part in the Chancellor’s statement about investment in net zero and in the NHS, but perhaps the Minister will say a little more on that. I suspect that although he will accept that ICBs should have regard to the overall commitment, he will say that the new clause is unnecessary as NHS England already has a commitment that will percolate down to ICBs. We would say that NHS England can achieve that target only by working through ICBs, which will, of course, have the ability to commission more than £100 billion-worth of services.

We may end up yet again in the realms of the permissive versus prescriptive debate, but the power of public sector procurement is a massive issue, and there is no bigger part of the public sector than the NHS, which is the responsibility of the Minister’s Department. We should be very much on the front foot in using that to deliver the commitment to net zero.

Of course, we have yet to see what will replace the public contracts regulations in Government procurement as a whole. It is hoped that the same commitment to green issues will be in the mix somewhere, but until we know what that looks like, the new clause presents an opportunity to enshrine in law a commitment that I think most if not all Members want to see delivered.

--- Later in debate ---

[Justin Madders]

I am grateful to the Minister for his positive comments. We were probably pushing our luck with getting a formal commitment from him, but it sounds like we are probably as close as we are going to get to progress on the matter without pushing the new clause formally to a vote. We will keep a close eye on the issue and will, no doubt, come back to it if progress is not made in orderly time. I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 50

Access to innovative medicines and medicinal products review

“(1) The Secretary of State must undertake and publish a review of the use by the NHS of innovative medicines and medicinal products.

(2) The review must—

(a) conclude before 31 December 2022;

(b) consider ways to improve the use of innovative medicines and medicinal products within the NHS in England.

(3) The review may consider—

(a) the creation of a specific pathway to assess medicines and medicinal products for rare and less common conditions;

(b) improvements to the way in which patient and clinical experience is accommodated when considering the adoption of new medicines and medicinal products.”—(Alex Norris.)

This new clause would require the Secretary of State to carry out a review of the assessment and use of innovative medicines and medicinal products, and to consider how to improve access to medicines and medicinal products for people with rare and less common conditions in particular.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

The new clause would put a helpful requirement on the Secretary of State to undertake a review of the assessment and use of innovative medicines and medicinal products, which I believe would be a positive step forward. Medical innovation, including new drugs and cutting-edge treatments, produces life-saving and life-changing results, and those benefits are particularly felt by those with rare and genetic diseases.

--- Later in debate ---

[Dr Whitford]

I wonder whether the hon. Gentleman shares my concerns after leaving the European Union about access for clinicians, and indeed their patients, to the European reference network, which helps to provide advice and treatment and has co-ordinated research, through the European Medicines Agency, into these rare, often childhood, diseases? They can be studied much more easily in a population of 500 million than one of 60 million.

[Alex Norris]

I am grateful for that contribution. It is axiomatic that, if we are talking about diseases that affect small populations in this country, growing the field of people who are affected so that we can undertake better research, trials and treatment can only be a good thing. I hope that the Minister might touch on how he is ensuring that we are not disadvantaged in that way. When we add up the nearly 8,000 diseases, we are talking about 3.5 million people—one in 17, so one person on the Committee, basically—who will in their lifetime be affected by a rare disease. So actually they are not so rare at all. It is really important that we are meeting that group of people’s needs, but access to medicines and medical devices remains a problem, which is why such reporting for rare conditions is so important.

At the moment, approved medicines are available for only 5% of rare diseases and, even where licensed treatments exist, patients can face an uphill battle in accessing them on the NHS. I am sure that most of us will have at least one case of a young constituent who desperately needs medicinal cannabis to treat epilepsy. There is a political consensus that this is the right thing to do, and we ought to do it. That has been a settled matter for at least three years now, but frustratingly it is still not getting through, and that is a pattern across rare diseases. Perhaps that points us to the conclusion that the current assessment process is not quite accounting for the unique challenges presented by rare and ultra-rare diseases.

I do not think that the Minister will want to be drawn on the National Institute for Health and Care Excellence methods review, because we are in that process. I have spoken in multiple debates about my enthusiasm for NICE, and its processes and expertise, but clearly something is missing. My working theory is around evaluation. Again, if we have a small patient population, the data is noisy and there are higher degrees of uncertainty due to the small sample sizes. That leads us nicely to the point that the hon. Member for Central Ayrshire made about trying to grow those pools. At the moment, we are unable to get first-in-class treatments in many cases, which we should want to do something about.

Herein lies the squeeze, as the medicines for rare and ultra-rare diseases are often assessed by processes that were designed for drugs with larger target populations. The statistics are a bit of an apples-to-oranges comparison, which creates a severe disadvantage. The purpose of the new clause is to get the Secretary of State to report generally on how we are ensuring that we are world leading and meeting population need, and then to drill down within that on how we are ensuring that the system for rarer conditions is fit for purpose. As I say, I am conscious that the methods review is ongoing, but I hope that the Minister might at least give us a sense of the general policy direction in this area, and what we might look to do differently in the future.

--- Later in debate ---

The Government published the new United Kingdom rare disease framework in January 2021, outlining the key priorities for rare diseases in the UK over the next five years. One priority area, identified through the national conversation on rare diseases, is to improve access to specialist care, treatments and drugs. Development of nation-specific implementation plans for this priority are under way across the four UK nations and will involve further engagement with the rare disease community. I believe these are the right steps to take, and I therefore encourage the hon. Gentleman not to press his new clause to a Division.

[Alex Norris]

I am grateful to the Minister for his full answer. He mentioned reviews around the innovative medicines fund and NICE methods, and it is probably wise for us to let those processes play out before looking at anything else, so I do not intend to press the new clause to a Division. However, I will leave the Minister with some final thoughts on NICE methods.

First, I hope there will be a parliamentary moment for us to engage with that and have those conversations. The process has independence for a very good reason, but we should still have views on its overall direction. I want to flag ahead of that—with a focus on combination therapies, particularly in the cancer space—that we are understanding better every day how different therapies used together can have an incredible aggregate impact on the individual.

I do not think it is breaking any great state secrets to say that the problem is that the way we pay for drugs in this country is an imperfect market. Do not get me wrong; it has found a balance, but one problem is that the treatments are—funnily enough—often priced to what we can afford to pay for. That is fine until we need to combine two different treatments from different providers, when it becomes really challenging to work out how to apportion that. If we are to achieve the innovations that we need, particularly in cancer, we will need a good answer to come out of that review.

I hope that the Minister has a watching brief on that review, and that when NICE has finished, we can have a good conversation about the outcome to ensure that it supports the goals that I think we all have. I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 51

Duty on integrated care partnerships to prepare and deliver a Best Start for Life strategy

“(1) The Local Government and Public Involvement in Health Act 2007 is amended in accordance with subsection (2).

(2) After section 116B (substituted by section 20 of this Act) insert—

‘116C  Duty on integrated care partnerships to prepare and deliver a Best Start for Life strategy 

(1) Each integrated care partnership must—

(a) assess the needs of expectant parents, infants and young children in its area;

(b) prepare and publish a strategy to improve outcomes and reduce inequalities among expectant parents, infants and young children;

(c) consult parents and carers in the area when developing the strategy;

(d) monitor and evaluate the effectiveness of the strategy.

(2) Local authorities, NHS bodies and other relevant partners must—

(a) cooperate on delivering the strategy;

(b) have regard to the strategy when exercising their functions.’”—(Alex Norris.)

This new clause would require each Integrated Care Partnership to prepare and deliver a “Best Start for Life” strategy, in cooperation with relevant bodies.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

I cannot quite remember on what day this new clause was submitted; it is towards the end of the new clauses but not at the very end, so that probably carbon dates it by 10 days or so. Nevertheless, we had some news in this space from yesterday’s Budget. We are in the strange situation of having seen effective early intervention services, such as Sure Start, take a clobbering for a decade, and then getting paid back pennies on the pound and being supposed to feel grateful for it. We are not. Nevertheless, there needs to be a commitment at all levels of Government and local government—and, in this case, integrated care boards—to have a real focus on early years.

The first 1,001 days of a child’s life, from conception to age two, are crucial. Getting things right in this period can determine what kind of life a child has and their health, wellbeing, cognitive function and psychological make-up. During those early years, a baby’s brain grows rapidly, and it doubles in size within the first year of life. As is so well established, child development is influenced by early experiences and environment, which means that it is so important to ensure that little ones in our communities get what they need—care, nurture and support—while ensuring that they are protected from neglect, harm and stress.

As the Government’s strategy in this space recognises, getting things right impacts not just on the lives of our children, but on our entire society. By ensuring that children get what they need at an early age, we can target some of the big issues that we have talked about for the last two months in this Committee: physical and mental health issues, pressures on the NHS, crime and antisocial behaviour, and drug and substance abuse. So much of that leads back to the early stages in life, and this is a matter of established science. There is no doubt that in this country, we are not very good at doing something about that. Six months or maybe even a year ago—time flies—we had a fantastic Westminster Hall debate, led by the right hon. Member for South Northamptonshire (Dame Andrea Leadsom), who chaired a very good review in this space.

There is barely a leaf’s width of disagreement on this issue between right hon. and hon. Members of all political persuasions. The common diagnosis for why we have not made more progress is that we know that such things save public services money in a generation’s time, but we cannot demonstrate that in a cashable savings way that passes Treasury processes. I am afraid that I did not see anything yesterday to suggest that that fight is yet being won, and I hope the Minister and his colleagues are doing everything in their power to argue for early interventions. Frankly, I would argue that for pretty much all Members present, the bulk of the returns will come when someone else is sitting in our seats and our roles are somebody else’s dreams, but that should not stop us acting, because it is so significantly in the national interest and in the interests of our communities.

There are huge inequalities. The most basic health statistic is that a child born in my city will live for seven fewer years than one born in the City of Westminster—never mind the yawning chasm of almost twice that in healthy life expectancy. That is the result of smaller inequalities that all add up to different life paths: family income, financial stress, smoking and alcohol use, and access to care and services. We know that the 1,001 critical days from conception are the moment to offer really good-quality support. Families receive support from a wide range of services, including maternity, health visiting and early years, and perhaps children’s social care, mental health and paediatrics.

As well as the inequalities, there is complexity. I have mentioned five different organisations with five different uniforms, five different organisational plans and five different organisational cultures. Someone has to pull that together. We have been told throughout proceedings on the Bill that that is exactly what integrated care partnerships are here to do, so let us put a responsibility on them to do so, and to have a plan. I dare say—the Minister might say this himself—that they are more than likely to want to do that themselves, and that would be a very good thing, but I do not think we can allow variance. This should be important for everybody and all footprints should be doing it, so that the first 1,001 days are given priority in new health systems. That would have a significant impact on the long-term health and wellbeing of our country.

[Dr Whitford]

I rise in support of the new clause. It is important to shift the narrative from what is often a structural focus on the NHS, and catching people when they fall, to looking at wellbeing and population to allow people to be healthier and live higher-quality lives for longer.

The hon. Member for Nottingham North mentioned the slowing down of improvement in life expectancy and the variation in life expectancy, but the bigger issue is the failure to improve healthy life expectancy. The 20 years of unhealthy life expectancy faced by many across the UK, particularly in more deprived areas, put pressure on the NHS, and we have seen that come home to roost over the last decade.

A lot of those health issues, or unhealth issues, are laid down in childhood. I am vice-chair of the all-party parliamentary group for health in all policies, which conducted an inquiry into the impact of child poverty. A figure from the Faculty of Public Health that has stayed with me is that the UK loses 1,400 children a year as a direct result of poverty, including by immature birth, small birth weight, foetal alcohol syndrome, fires, road traffic accidents, alcohol and drugs, violence and suicide. That is the number of students in a large secondary school, and if the roof of a large secondary school were collapsing every single year, we would do something about it.

Often, the time to do something about that is in the 1,001 days from conception forward, as the hon. Gentleman said. That means looking at maternal health and nutrition, which is why the early years collaborative in Scotland led to the Best Start grants to mothers and children at birth, on entering nursery and on entering school.

One internationally used measure on the health of our youngest children is infant mortality—death perinatally or in the first year. In 2014, England and Scotland had the same rate of 3.6 per 1,000 live births. In Scotland, we have managed to drive the rate down to 3.2, but in England, it is currently at 3.8. In some poorer areas of the UK, the rate is worse than in parts of the global south and the developing world. That is a brutal statistic.

We talked yesterday about maternal and infant deaths, but this also relates to the attainment gap and other issues faced throughout life by those who struggle in childhood. Investing in early years saves money in the long term. That might be the pitch to the Treasury: if we gave more children a decent start in life, fewer would struggle in the education system, fewer would struggle to get jobs, and fewer would be trapped by addiction or caught in the criminal services system. Instead of picking up the pieces later through the NHS or other public services, surely we should be investing in the best start in life for all our children.

--- Later in debate ---

[Alex Norris]

The point that the hon. Member for Central Ayrshire made about the UK losing 1,400 children a year is sobering. Whatever comes out of the process that the Minister mentioned must to be different from what we have today, or we will keep repeating that mistake. I shared the hon. Lady’s view about the pitch to the Treasury, but we will have to demonstrate that planning cycles in this country are mature and flexible enough to reflect the fact that not everything can be delivered, and show immediate returns, before the next general election. It is a challenge, and we will have to do better in that space. I am grateful for the Minister’s response, and he addressed my concerns very well. I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 52

Plan for implementing recommendations of the Independent Medicines and Medical Devices review

“The Secretary of State must, within six months, publish a report containing a plan for the implementation in full of the recommendations of the Independent Medicines and Medical Devices review that have hitherto not been implemented.” —(Alex Norris.)

This new clause would require the implementation of any remaining recommendations from the IMMDS report.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

In February 2018, the noble Baroness Cumberlege was asked to carry out the independent medicines and medical devices review into the experiences of people—generally women—who had been treated with Primodos, sodium valproate or pelvic mesh implants. In very many cases, they had to battle for decades to be heard. They were gaslit, belittled and ignored at every turn. Some of the ways in which they were treated were just astonishing, and so upsetting. However, through that report they got their deliverance. They were vindicated: what they said had happened to them had happened to them—even though they had not been believed—and it should not have done. Acknowledging the pain that had been caused to these families was a big start in helping them come to terms with what they had experienced.

The excellent review team set out nine ways in which things would be made better, or at least a little bit easier, for those people now, and to try to prevent future incidents. Those nine recommendations should have been accepted in full. Instead, we have seen from the Government a pattern of accepting things that I suspect they were already keen to do, but otherwise taking the families for a long walk when it comes to the harder and more significant things that the Government clearly do not want to do. In aggregate, it has become a refusal to do right by these families, and that is a really poor decision.

This new clause seeks to attend to that by saying that within six months, the Secretary of State must publish a report containing a plan for the implementation of the recommendations in full. Of the nine, only four are being implemented in full and, frankly, that is not good enough. I am pleased that there has been an apology, and the families were too. I was also pleased to see legislation for a patient safety commissioner. We were lucky that the Medicines and Medical Devices Act 2021 was in front of us at that time, because it gave us a moment to introduce that and a devices database, which the hon. Member for Central Ayrshire and I pursued during proceedings on that Bill. Those things have a bit further to go, but they were significant, as were the promises of cultural reforms at the Medicines and Healthcare products Regulatory Agency. We will wait to see meaningful change there. With the remaining five recommendations, there has been a mixture of in-principle acceptance, partial acceptance and, in some cases, outright denial. I do not think that is good enough, and the new clause seeks to change that.

These are the bits that we are still missing. Recommendation 3 calls for:

“A new independent Redress Agency for those harmed by medicines and medical devices”.

The Government responded that they did not accept that. The problem is that families are therefore left to rely on conventional civil and legal routes. Those are expensive and long, and who do the families sit against in the courtroom? Very big companies with very big legal teams, so there is a significant imbalance. The whole point is that, as recommendation 3 goes on to state:

“The Redress Agency will administer decisions using a non-adversarial process with determinations based on avoidable harm looking at systemic failings, rather than blaming individuals.”

That would have been really significant, but we do not have that. Instead, families are left stuck in the court system for as long as they can stick at it.

Recommendation 4 states:

“Separate schemes should be set up for each intervention—HPTs, valproate and pelvic mesh—to meet the cost of providing additional care and support to those who have experienced avoidable harm and are eligible to claim.”

Again, the Government do not accept that. These families meet exceptionally challenging needs day after day. Some have lost their house; some have had failed relationships; and all struggle with mental health, or certainly distress, as a result of what has happened, and we are not doing enough to help them. This should have been done, if not on day one, at the very first possible moment for support, rather than us expecting them to fall back on the conventional system, as they did. What have they gained by their vindication?

Recommendation 5 states:

“Networks of specialist centres should be set up to provide comprehensive treatment, care and advice for those affected by implanted mesh; and separately for those adversely affected by medications taken during pregnancy.”

The Government accept that only in part; it is particularly with regard to valproate that those affected will not get those centres. I will listen carefully to the Minister’s justification for that. I understand that valproate is different, in the sense that its use is ongoing in certain situations where that remains medically appropriate. However, the lack of specialised knowledge is a real issue. If there is not specialisation, we need a real sense that there is a universal step change in knowledge and experience in this area to give us greater comfort.

Recommendation 8 states:

“Transparency of payments made to clinicians needs to improve. The register of the General Medical Council (GMC) should be expanded to include a list of financial and non-pecuniary interests for all doctors”.

That is very basic. There were relationships between clinicians and big drug companies that were unknown to the families when certain treatments were suggested. The Government accept the recommendation in principle, but will not use the General Medical Council model, preferring to go practice by practice. That is big mistake. Our constituents can go to one easy, obvious place—our website—to find out our exact financial interests if they have concerns or just want to know them. We ought to be able to do the same, through the GMC, when it comes to doctors. Again, there is an unwillingness to move quickly enough to resolve these issues.

Finally, it remains surprising that the Government have not availed themselves of recommendation 9. I will listen carefully to the Minister’s response on this point. It states:

“The Government should immediately set up a task force to implement this Review’s recommendations. Its first task should be to set out a timeline for their implementation.”

Of course there should be a taskforce, including families and the broader aspects of the state, to do that. Again, the Government say they accept the recommendation in part, but the reality is that they have no plans to establish an independent taskforce. There is a patient reference group, and we of course support its work, but it is not in control; it is not at the table. The problem is that these things were done to families; they had no agency and no say. The solutions that come out of this cannot follow that same model. Once again, families are having things done to them, rather than being worked with.

I meet representatives of these groups frequently, as I know colleagues do. I like meeting them. These are good people who have been through incredible things and have extraordinary dignity and courage, not to mention that they are brilliant campaigners. They are probably sick of seeing me, and I would rather see them in happier circumstances. When I ask them what is next, they say that they are campaigning again. They campaigned over many years to be listened to, and were proven right in the most absolute terms, but they feel they have to campaign again to get the justice that should flow from that report and from their vindication. What an extraordinary demonstration of how we have let them down. They fought for too long. It is time that we stood up for them and did right by them by implementing the recommendations in full; otherwise we fail them again. I hope to hear of significant progress from the Minister.

[Dr Whitford]

I support the new clause. For a surgeon, knowing that an operation that they were trained to carry out, and performed in good faith, has caused harm is one of the worst things that can happen. I remember how I felt in the mid-1980s when we began to realise the impact of contaminated blood. It had a huge impact on how I operated. I used special diathermy techniques to avoid blood transfusion in all elective circumstances, and that is something I carried on throughout my time doing breast cancer surgery.

In this case, there may well have been doctors who were dealing with device companies and so on—that regulatory declaration is absolutely needed—but there will be a much greater number of surgeons who were using a device that was licensed and was given to them as the correct, safe device to use.

I find it shocking that although the report was commissioned by the Government, they have accepted fewer than half of its recommendations. The others directly relate to patients who have suffered harm, whether that is the women who had vaginal meshes inserted, or the mothers of children who were harmed by the use of Primodos or sodium valproate.

Sodium valproate is still an excellent anti-epileptic and will not disappear, but it is not a matter for specialist centres. It is so widely used that it is critical that within primary care and on product boxes it is made clear that women who are looking to conceive or who are of child-bearing age should not be left on Epilim; that should be discussed with them right from when they are young teenagers, so they can think about the impact later on.

The recommendations that have not been accepted are not to do with reorganising licensing, or a yellow card system; they are all recommendations that relate to women. That is really disappointing. The redress for them—the setting up of specialist centres to try to repair the damage as far as possible—is what is not being provided. The Government should look at the fact that those are the recommendations they have skirted around and not accepted. These women and the children affected have gone through enough.

--- Later in debate ---

I appreciate that the objective of the amendment is to hold the Government to account for implementation of their response. The Government have already committed to publishing an update on implementation; we intend to do that by summer 2022. I believe that significant progress on the recommendations has been made, but I am conscious that the shadow Minister, with his depth of knowledge in this area, may wish to press further in the coming months. I suspect that he will rightly continue to hold the Government to account.

[Alex Norris]

I am grateful for colleagues’ contributions. The comments of the hon. Member for Central Ayrshire presaged what the Minister said: yes, the Government have been able to do the more strategic aspects of this, but they have done half a job. The half they left out relates to people who have fought for so long just to get a little support, and recognition that they have been badly wronged in a way that significantly changed their life. They really do not ask for much—just a bit of support. It is not a nebulous or open-ended ask; it is just for what was in the report, and that does not seem too much to me.

The Government have been in defensive mode for a long period on this issue, but I desperately hope that they do not think they have done the job, because they really have not. I also hope that they do not think these women will go away, because they absolutely will not, and a lot of right hon. and hon. Members in this place want to help them and give them a platform from which their voices will be heard. A good way to act would have been through the new clause. With that in mind, I intend to press it to a Division.

Question put, That the clause be read a Second time.

--- Later in debate ---

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

The new clause is a fitting follow-up to new clause 52, in the sense that the theme of the report was that, yes, dreadful things happened, but—as the hon. Member for Central Ayrshire said—largely with a complete lack of knowledge among clinicians, who were just following the guidelines, as they were supposed to and had been trained to. A common theme beyond that is that this happened to women, and when women tried to express their concerns, the system was not geared up to listen. Instead, the response of the system was to write them off—some of the name calling will probably not amaze us, but it should.

The new clause seeks to ensure explicitly that local care boards take into account the views of women on reproductive health. High-quality reproductive healthcare should be accessible and individualised at each stage of a woman’s life, from puberty and through the years of menstruation to the menopause and beyond. This is something that we will discuss tomorrow through the private Member’s Bill of my hon. Friend the Member for Swansea East (Carolyn Harris). She will put the case well, I have no doubt.

The system should enable women to decide whether, when and how often to have children by informing them about, and providing easy and timely access to, the full range of contraceptive methods. Maintaining good reproductive health and wellbeing has profound and positive long-term effects for women and wider society. However, at the moment, inherent system fractures in the commissioning and delivery of reproductive healthcare services mean that many women are left struggling to access basic reproductive care, including contraception and gynaecological cancer screening.

The impact of the current situation is stark. Almost half of British women have experienced poor sexual and reproductive health, and that figure should give us pause. We know that since the Health and Social Care Act 2012—again, this is something in that Act that we should want to change—reproductive healthcare has been compromised by a lack of strategic prioritisation and prevention, a deeply fragmented commissioning landscape, and of course that ongoing theme of significant cuts to public health, which in this case include a 14% real-terms reduction for sexual and reproductive health services. Again, that has been felt more by poorer communities, and all those factors have resulted in gaps in the reproductive care pathway, creating disconnected and disjointed care for women. For example, in many areas of the country, women are not able to access a fitting for an intrauterine device—one of the most effective contraceptive methods—or cervical smear tests in a similar healthcare setting, meaning that they have to go through multiple invasive exams in different settings. Of course, it is important that those tests take place, but we should seek to make it the easiest process that it can possibly be.

Women approaching the menopause are not able to access treatment for heavy menstrual bleeding at community clinics or GP practices, because many are not commissioned to provide that service or lack the funding or trained staff, resulting in those women being bounced around the system while living with obviously debilitating conditions. This Bill is an important moment to tackle long-standing structural challenges in reproductive healthcare. If we are truly moving towards greater integration and collaboration within the healthcare system, this is a really good chance to implement holistic women’s reproductive healthcare services at a regional and local level. Through listening to women and integrating care around the needs of the individual, rather than the institutions, we can deliver holistic care across the breadth of reproductive healthcare.

I know that there is a broader duty in this Bill for integrated care boards to promote the involvement of their patients and carers in decisions about the provision of health and care services, as well as having regard for inequalities. This new clause builds on that by wiring in engagement with women, because it is not happening. Again, if we just keep doing things in the same way, we will get the same outcome, so this is an opportunity to design a healthcare system for women that listens to women and builds in accountability. That will help ensure that reproductive healthcare pathways fully meet the needs of those who they are meant to serve, which would be a very positive outcome.

--- Later in debate ---

[Edward Argar]

The hon. Lady is absolutely right to raise that. We need to get across, loud and clear, to our future clinicians almost right from the start—from their training and early education—the message that everyone’s health concerns matter equally, subject, obviously, to clinical decision making. I hope and believe that HEE and others will engage with that process in the context of the women’s health strategy. We do not want it to be a document that just sits on a shelf, or want it to look at issues in a siloed way; it should look at them across the piece. Over many years, there have been strategies on particular aspects of health. In the strategy, we seek to bring together a whole range of factors, so that we can look at how women interact with the healthcare system, and how to meet their needs holistically.

We want to maximise the independence of ICBs, so that they function in the way that best suits the needs of their patients and their organisations. We are therefore keeping their legislative obligations proportionate; that brings us back to a debate that the Committee has had multiple times about the permissive nature of the legislation. I agree that appropriate representation is essential in healthcare planning. I fear that the new clause is overly specific and not necessarily in keeping with the obligations on ICBs set out in clause 19 on general functions.

The Bill already puts obligations on ICBs that will help to ensure that relevant groups are fully represented and consulted in decision making. In particular, ICBs will need to ensure that they have taken appropriate advice from a broad range of those with professional expertise. As the work of ICBs will inevitably cover reproductive health, that requirement ensures that relevant groups are included in this work. Furthermore, as we discussed in the opening sittings of the Committee, local areas will have the flexibility to determine any further membership of the ICB beyond the minimum for which we have legislated. That discretion will allow local areas to ensure appropriate representation.

On working in partnership with the non-profit sector and local community groups, I recognise the essential role that those organisations and groups play, and agree that they should be involved in strategic decision making where appropriate. Each ICB and their partner local authorities will be required to establish an integrated care partnership. We expect the ICP to bring together organisations from across health, social care and public health, and representatives from wider areas where appropriate. That could include organisations from the voluntary and community sector. The ICP will be tasked with promoting partnership arrangements and developing a plan to address the health, social care and public health needs in its area. As that will include reproductive healthcare needs, we would expect relevant local groups to be represented. The ICB and local authorities will have to have regard to that plan when making decisions. That will enable more joined-up planning and provision, both in the NHS and by local authorities, which will enhance the services that people receive.

Existing and proposed duties already address the concerns underlying the new clause and ensure effective public involvement. We have concerns about imposing additional duties on individual services. Our approach enables local NHS bodies, supported by national guidance, to decide how best to involve patients and the public in the planning of commissioning arrangements, and in developing and considering proposals to change them, so we are not convinced that the additions in the new clause in respect of reproductive healthcare are necessary.

[Alex Norris]

I am grateful for the contribution from my hon. Friend the Member for Bristol South. Many people will be looking with great interest at what happens tomorrow. She spoke about the menopause not having been on the political agenda for such a long time. I think that that has changed, and not before time, so we are all very much looking forward to what will happen.

We have tested the Minister on the permissiveness point quite a lot, so by this, the 22nd sitting of the Committee, I think it is possibly an established fact, and I do not intend to divide the Committee, but I do want to come back on what he said about the sufficiency of the duties as drawn. When we have pushed for individual plans for each ICB—say, on inequalities, on the first 1,001 days and on drugs and health—there has almost been a sense of, “Well, of course these bodies will want to do that. It will be their local decision, but of course the evidence will drive them to do that.” I do not think we can say, on women’s health, that that is an “of course”, because we know that actually, historically, it can be very much an afterthought.

The thought that I might leave colleagues with on this issue is that we are having a growing conversation in this country about misogyny, and one of the things that you will hear men say a lot—I have said this myself, because I mean it—is, “We have to hold one another to account for the things we say and the way we act.” I completely agree with that. In that spirit, we have to understand that if a lot of the basic reproductive healthcare things that we are talking about today happened to men, we would be doing them in McDonald’s drive-thrus. It is as simple as that. Therefore, if we are to have an honest conversation with one another about misogyny in this country, it is that sort of thing that we mean. It is not always about pointing fingers and blaming, or policing jokes, which I think is important; it is actually about saying that services are different because these things do not happen to us and we should be more mindful of that and should want to change. I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 54

Enhanced data collection

“(1) The National Health Service Act 2006 is amended as follows.

(2) After section 14Z43 (inserted by section 19 of this Act) insert—

“14Z43A  Duty to develop data collection systems

Integrated care boards must—

(a) develop single whole-system IT systems across the whole of their integrated care system with the explicit purpose of supporting data collection and sharing;

(b) prioritise the use of those data systems for streamlining patient pathways;

(c) establish mandatory standards for patient-initiated follow ups; and

(d) use the data systems developed under paragraph (a) to report on a regular basis performance against improving patient outcomes in line with the standards established under paragraph (c).””—(Alex Norris.)

This new clause requires ICSs to develop digital data collection and sharing systems, and use them to track performance against mandatory standards, with specific regard to patient-initiated follow ups.

Brought up, and read the First time.

[Alex Norris]

I beg to move, that the clause be read a Second time.

I keep going, Ms Elliott. Again, you can perhaps file this under gluttony for punishment. I do not intend to talk for very long about this new clause. I am sure that the Minister will be able to give us comfort easily on the point of new clause 54. It is just to develop the point about data one last time before our carriages turn into pumpkins.

A specific part of the Bill deals with data, and we had some very good conversations at that point. I will not repeat any of that. I will explain what I am chancing my arm at in new clause 54. I talked previously about systems and the problems with systems talking to one another. Here, we are asking integrated care boards to develop

“single whole-system IT systems”.

That is perhaps at the top end in terms of what should be aspirational and what is in fact achievable, but I do want to pursue the point a little.

Data is critical, as we have said before, in driving improvements. NHS England’s own website talks about the need to use it to improve services and decision making, to identify trends and patterns, to draw comparisons, to predict future events and outcomes and to evaluate services. But to do that, we have to have some sense of consistency. I will not repeat the arguments around the General Data Protection Regulation—we had those at length—but that shows the challenges if we do not get it right.

Going down to ICS level, if we are going to have a system that really does harness all the information, we need systems that talk to one another. Therefore, the prescription in proposed new subsection (a) is that it is a single system. As I have said, that is the stretch target. What I am hoping to get from the Minister is a sense of where he thinks this will land. Is it the same organisations using the same systems but trying to find a new way to do them, or will there be some new, novel approach to how we support footprints to do that? It is an established fact that data is going to be really important to local systems, so we want to give them the fairest wind to make the best use of it that they can.

[Dr Whitford]

On new clause 54, I just want to speak to proposed new subsection (d)—the use of data to assess performance against outcomes. Between 2009 and 2019, there was really no significant national audit of quality of breast cancer services in England, even though some of that audit had been carried out in previous years. Part of that was due to the fracturing of the system from the social care Act. There might be only one breast unit within an area, and quality was left to commissioners. How can commissioners measure whether a local breast unit is treating people properly or achieving the aspired-to targets?

In Scotland, 19 of the commonest cancers are audited; I was involved in developing the breast cancer standards in 2000, and they have been updated many times since. They are assessed annually with an annual peer review conference, where clinicians will openly discuss the challenges they face and therefore will share the solutions many of them have come up with. The clinical things that we know will affect the survival and outcomes of our women in the future are all set as national benchmarks. It is important that, while data would be collected locally, it is benchmarked against national standards.

The Getting It Right First Time project was restarted in England a few years ago but, to my knowledge, although the Getting It Right First Time for breast cancer report was completed at the end of 2019, I have not seen it published. That appeared to be due to the election in December 2019; perhaps the Minister can clarify whether the breast cancer GIRFT report has now been published, when it might be published and what other GIRFT reports have come out.

The problem is that, even if that report were published now, two years after its completion, it would largely be based on data from 2018, and therefore clinicians would shrug their shoulders and say, “Out of date.” It is important that data is used in a timeous manner to audit as quickly as possible, so that the audit loop can be closed and services improved. Having led on this process in Scotland, I saw the change in standards between 2001, when we began the first assessment, and 2005, and it is an incredibly satisfying, not frightening, thing for clinicians to see year on year the quality of care delivered by their unit driven up. There must be national standards, but local audit.

--- Later in debate ---

As a result of the above, I do not believe that adding an additional duty to ICBs would be necessary, as the work is already under way.

[Alex Norris]

This is not something that we will be able to resolve with top-down prescription, but I have made the point that I hope we will do everything we can at a national level to model best practice, to demonstrate best practice and to give our local systems access to best-practice systems, because that will be very important. On that basis, I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 56

Domestic violence training for GPs

“(1) The National Health Service Act 2006 is amended as follows.

(2) After section 83B (inserted by paragraph 3 of Schedule 3 of this Act) insert—

“83C  Duty concerning domestic violence and abuse

(none) Integrated care boards must ensure that specialist domestic violence and abuse training, support and referral programmes are universally available to all general practitioners.””—(Alex Norris.)

This new clause adds a requirement for specialist domestic violence and abuse programmes to be available universally throughout general practice.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

Domestic abuse is an issue of significant interest across this place. We know that two women a week are killed by a current or former partner in England and Wales alone. As we mentioned the other day, a quarter of women will experience domestic abuse in the course of their lifetime, which has devastating effects. It impacts on both the physical and mental health of survivors and their children, and it has a terrible cost in general to everybody, including a financial cost.

New clause 56 would impose a duty at a local level to ensure that GPs have access to specialist domestic violence and abuse training. It is something that would be very welcome, and we are proposing a duty for integrated care boards to provide that. GPs are a credible point of contact for people in violent relationships. Some 80% of women in a violent relationship seek help from health services first. In some cases, that is their only contact. Training for GPs is vital to ensure that such contact is of the best possible quality. A study of women in violent relationships in the Netherlands found that 50% of women who did not speak to their GP about the matter would have done so if the GP had been in a position to approach it. Moreover, 50% of the women who did talk to their GP did so because they hoped to be referred on, so they wanted to have a high-quality conversation with someone who knew the system.

From my time prior to this place and my experience in Nottingham, I have a lot of enthusiasm for the IRIS programme—the identification and referral to improve safety programme. A trial carried out by Bristol University found that the training programme led to up to six times more women receiving the help they needed, and that it boosted the number of referrals to specialist domestic violence agencies. After IRIS training, GPs reported being better able to assess domestic violence risks and a greater awareness of services, while 99% of service users felt listened to and 87% felt safer.

The evidence is that such training works. This is of course not the way in which we should write a new clause, but I am saying that IRIS should be universal or something like it. I would leave the “something like it” to the provider market and to commissioners but, in general, the principle is that all GPs should have training so that they can understand and act on domestic abuse and have the right resources to provide support and make skilful onward referrals, so that the system can wrap its arms around an individual who is trying to get out of an abusive situation. That would be exceptionally important for such women, and I hope the Minister will have some thoughts about how we can get to a universal, IRIS-like level of engagement with our GPs.

[Edward Argar]

The new clause would require ICBs to provide specialist domestic violence and abuse training, support and referral programmes to all GPs, with the aim of strengthening the health response to domestic abuse and improving links between the NHS and voluntary sector support for victims. We have concerns about the new clause, which is why we cannot accept it, but I hope that I can set out to the shadow Minister my reasoning.

Domestic abuse, as we discussed yesterday when considering another proposed new clause, is a terrible crime, and it can have a devastating impact on victims and survivors. It is also important that we remember that children are often just as much victims as the victims themselves, through the experiences that they have of domestic abuse and domestic violence. The Government are clear that there is absolutely no excuse for abuse. Tackling domestic abuse and supporting victims, survivors and their children is a key priority for Government, now more than ever.

The Domestic Abuse Act 2021 and the forthcoming domestic abuse strategy will help to provide a whole-system approach to protect and support victims and their children. The measures in the 2021 Act seek to promote awareness by introducing a statutory definition of domestic abuse, and to recognise children, as I alluded to, as victims in their own right, in order to protect and support both, tackle perpetrators, transform the justice response, and drive consistency and better performance in the response to domestic abuse.

The 2021 Act also sets out the convening of local domestic abuse partnership boards, with healthcare representation. We recognise the key role that healthcare services play within a whole-system approach to tackling domestic violence. Healthcare services must identify signs of risk and harm, enable victims and survivors to come forward, and provide timely integrated care and support. We know how important it is that statutory agencies and professionals properly understand and react to domestic abuse. However, I hope that I can reassure the Committee that placing in the Bill a formal duty on ICBs to ensure that specialist domestic violence and abuse training, support and referral programmes are universally available to all GPs is not necessary.

General practice is delivered by multidisciplinary teams, rather than just GPs, and existing Care Quality Commission registration requirements include a review of practices’ safeguarding processes. In addition, NHSEI’s ICS people guidance sets an expectation that ICBs will foster learning and continuing professional development. Going further, the Bill, in proposed new section 14Z41 of the National Health Service Act 2006, imposes a duty that each ICB

“must, in exercising its functions, have regard to the need to promote education and training for the persons mentioned in section 1F(1)”

of the 2006 Act.

[Edward Argar]

I am grateful to the hon. Lady. In part, the reason is because this is sadly not a well drafted new clause. It is very narrowly drafted to GPs, not recognising the multidisciplinary nature of how healthcare is delivered in GP practices. I suspect that we all have correspondence from constituents—whether happy or unhappy—going to doctor associates, practice nurses and others. That is one of my key concerns, but let me articulate a little more what is already being done. I see where she is coming from. As I mentioned yesterday, I was the Minister with responsibility for victims of domestic violence, and of crime in general, when I was in the Ministry of Justice, so it is something that I am very familiar with. It is about raising awareness not just with GPs, but within the police and a range of agencies. My challenge, just before she intervened, was partly about the way the new clause is drawn, but let me articulate a little further our views on it. I am keen to do so before the business possibly collapses early in the House, and we have to adjourn in order that I can respond to the Adjournment debate.

Section 1F of the 2006 Act defines a wide group of people, covering persons who are employed, or who are considering becoming employed, in an activity that involves or is connected with the provision of services as part of the health service in England. That duty on ICBs would already cover general practitioners, but it goes wider. I appreciate that the new clause goes beyond training, so I will also discuss the support and referral elements that the hon. Member for Nottingham North talked about.

The NHS provides care and support to victims of domestic abuse through a range of healthcare services. This response is centred around ensuring that healthcare professionals are trained to spot the signs of domestic abuse and those at risk; to make safe and sensitive enquiry of the issue; to know where to refer people to get further support, and to know when and how to share information appropriately with colleagues and other organisations.

All NHS staff must undertake annual mandatory safeguarding training, which includes focus on domestic abuse. NHS England, NHS Improvement and Health Education England are reviewing mandatory safeguarding training for all health professionals to ensure that they are fully equipped with the key skills, knowledge and principles to protect all citizens. The Government published an online domestic abuse resource for health professionals and have developed a number of training modules with the Institute of Health Professionals, the Royal College of Nursing and the Royal College of General Practitioners.

From 2018 to 2020, the Department managed £2 million of funding for the domestic abuse pathfinder programme, which created a model health response for survivors of domestic violence and abuse in acute, community and mental health services. The pathfinder toolkit was published in 2020 as the result of emerging promising practice at our pilot sites, coupled with the expertise of the pathfinder consortium of specialist domestic abuse organisations, to encourage best practice across the health system. Pathfinder has given us a model for our response to domestic abuse in healthcare. It is a model for integrated, joined-up and trauma-informed care and support, with healthcare settings and the voluntary sector working together.

As the shadow Minister mentioned, the Department of Health and Social Care has also funded the IRIS programme, to which I pay tribute. IRIS is a training, referral and advocacy model to support clinicians in better supporting patients who are affected by domestic violence and abuse, and to increase the awareness of domestic violence and abuse within general practice. IRIS is recognised by the DHSC as good practice, and via the National Institute for Health Research we funded a study that demonstrated the effectiveness of the IRIS programme at scale. I am delighted to note that the study won the 2020 Royal College of General Practitioners research paper of the year award.

I am proud that the Government have championed the building of that evidence base. I believe that it would not be best or appropriate, however, for the legislation to require local health and care systems to adopt specific programmes. Indeed, such detailed requirements would reduce local health and care partners’ flexibility to meet the needs of their local populations or to engage with particular local organisations and expertise in delivering their programmes.

Beyond ICBs, I see a huge opportunity for integrated care partnerships to support improved services for victims of domestic abuse, sexual violence and other forms of harm, through better partnership working and joint planning of services. The Government have also developed a cross-Government strategy for tackling violence against women and girls, and will develop a cross-Government domestic abuse strategy.

As committed to in the tackling violence against women and girls strategy, the DHSC will continue to work closely with NHS England and NHS Improvement to promote evidence-based approaches to tackling violence and abuse through guidance and engagement with the new system.

[Alex Norris]

I am grateful to the Minister for his response. I am more than happy to wait for the domestic abuse strategy, but I really hope that such measures will feature in it, and that when the strategy goes around various Departments for their comments, the Minister will make a commitment—

[Edward Argar]

May I make the offer to the hon. Gentleman that I or the relevant Minister leading on this—whoever is more appropriate—will engage directly with him?

[Alex Norris]

That is very welcome, and in that spirit, I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 57

Cancer strategy

“Within 12 months the Secretary of State must—

(a) publish a new cancer strategy; and

(b) either designate a minister or appoint a national lead with responsibility for enacting its implementation.” —(Alex Norris.)

This new clause requires the publication of a new cancer strategy, with a minister or other person made responsible for its delivery.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

[The Chair]

With this it will be convenient to discuss new clause 64—Cancer treatment data reporting—

“(1) Beginning within 6 months of the passage of this Act, the Secretary of State must publish each month data on—

(a) the number of patients awaiting treatment for cancer,

(b) the number of patients with a cancer diagnosis, and

(c) what NHS’s previous estimate was of the number of patients who would have a cancer diagnosis at that point in time.

(2) Six months after the publication of the first report under subsection (1), and every six months thereafter, the Secretary of State must publish a report on the action being taken to reduce the number of patients awaiting treatment for cancer.”

[Alex Norris]

I am conscious of other business, so if I am interrupted, I will not take it as rudeness.

[Edward Argar]

We may be okay.

[Alex Norris]

New clauses 57 and 64 both relate to cancer. It is not quite possible to quantify the damage done by cancer in this country because we end up just throwing big numbers around. In the UK, there are 375,000 new cases and 166,000 cancer deaths each year. Each of those numbers represents a person with a devastated family. I lost my father to cancer in my infancy—35 years ago in January—and that loss is something that lives with a family for the rest of their lives.

We know that one in two people born after 1960 will be diagnosed with cancer. Our investment in cancer services is £5 billion a year, but the cost dwarfs that, at over £18 billion. Nearly 40% of cancers are preventable. Happily—this is something we should be proud of in this country—the developments that we are making in medical and technological areas mean that cancers are increasingly survivable, with the survival rate doubling in the last four decades. Better diagnosis and treatments mean that nearly 50% of those diagnosed with cancer in England and Wales now survive for 10 or more years, and there is no reason for that to stop increasing.

--- Later in debate ---

[Edward Argar]

I am grateful to the hon. Lady, who is distinguished in this field herself, from her previous career. She quite rightly highlights the importance of the workforce. Since 2010, in both radiology and radiography, there have been significant percentage increases in the workforce of those specialist professions. However, she is right to highlight that, while we have seen a significant percentage increase, in absolute terms we still need to do more to grow those professions. We have plans in place to do that, but that is a slow task; it can, in some cases, take up to 10 or 12 years to become an experienced specialist in that field.

On those increases since 2010, the Government would argue that we put measures in place, but it is also important to recognise that the previous Labour Government were working on this as well, hence the pull-through; those radiologists and radiographers did not magically appear immediately after 2010. There were programmes in place before and after that, so it is right that we recognise the contribution of the Opposition when they were in Government.

Finally, the new clause also seeks to place a Minister or national leader in charge of that new cancer plan. My ministerial role includes responsibility for elective recovery and recovery from the pandemic—our plan to tackle those waiting lists. As the shadow Minister knows, my hon. Friend the Member for Bury St Edmunds (Jo Churchill), the former Under-Secretary of State for Health, who briefly sat on this Committee, had responsibility for cancer services specifically, as does the new Under-Secretary. Dame Cally Palmer is the national lead as the national cancer director at NHS England and NHS Improvement. She has a distinguished career as chief executive of the Royal Marsden Hospital in parallel. We are jointly responsible for the current cancer plan. It is therefore unnecessary to include that new duty when we already have those accountabilities.

I will move on briefly to new clause 64, which we are considering with new clause 57. It seeks to legislate for an additional duty on the Secretary of State to publish data on cancer waiting lists, cancer diagnoses and action being taken to reduce the number of patients waiting for cancer treatment in England. Again, I understand the intention behind the new clause. Cancer is one of the greatest challenges to people’s health, as we set out. I would like to highlight first the fact that the Government are already delivering on the request for monthly publication of cancer performance data. Ensuring transparency of data is a priority. Each month, we publish official statistics on waiting list data, including the number of patients who began cancer treatment and waited longer than 62 days for treatment. NHS England also publishes monthly management data on the number of people currently waiting longer than 62 days for diagnosis or treatment. The new clause calls for data that is very similar to what is already published, and we therefore consider that it would be duplicative.

Secondly, on the request to publish predictions—that is not something that is currently done. Doing so would likely result in unhelpful poor-quality assumptions or modelling that could lead to expectations or an understanding that is not reflected in the reality of the data that comes through. While we look at all data sources internally, it would not be in the best interests of scrutiny and, potentially, patients to publish poor-quality predictions with a limited confidence factor.

Thirdly, there is no evidence of need. Following the success of campaigns such as Help Us, Help You, we have seen the public seek medical attention for symptoms that might be cancer, while cancer referrals from GPs have been at record levels since March. At the same time, the NHS has been delivering high-quality and innovative solutions to improve cancer care and treatment. We have announced funding for elective recovery, including cancer services, of £2 billion this year and £8 billion over the next three years, which will increase activity and deliver millions more checks, scans, procedures and treatments. We will continue to publish and review the monthly official statistics to monitor progress.

Finally, on the request for the Secretary of State to publish a report every six months on the actions taken to reduce the number of patients awaiting cancer treatment, I should state that the NHS has already undertaken extensive work to reduce the number of patients waiting for treatment and to continue progress in delivering the long-term plan ambitions for cancer. We will publish the elective recovery delivery plan later this year, which will set out how the NHS will deliver increased elective capacity and how cancer patients will be prioritised for access.

Furthermore, the NHS cancer programme already regularly reports on progress through both NHSEI and DHSC governance structures, through publication of monthly data on cancer waiting times and through regular communications products. We would therefore argue that the new clause is duplicative. While I assure the Committee that we are taking urgent action to reduce cancer waiting lists, we consider the new clause to be unnecessary.

[Alex Norris]

I am grateful for that answer, which reflects the current difference in public policy between the Government and the Opposition. At oral questions to the Health Secretary, I always ask and will continue to ask whether the Government’s position is that the current plans and status will be sufficient to meet the challenges and the backlog—we think they are not. While the system was overheated before the pandemic, it has been distressed by the last 18 months. We do not think that asking that system to meet both emergent and old problems will work. However, that is probably a point for oral questions and future debates, rather than this Public Bill Committee. On that basis, I will withdraw the clause.

As we are coming to the end of the debate, I might gently say to the Minister, on his point that the Government do not make predictions because they might be unhelpful in the future, that it feels as if, every time he goes on the news, the Health Secretary puts waiting lists up by another million in an extraordinary attempt to manage expectations. Was it 13 million last time? It just goes up and up. I do not think it is quite fair to say that Ministers do not do that—the Health Secretary, at least, certainly does. Nevertheless, that is no reason not to withdraw the clause, and I therefore beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

Ordered, That further consideration be now adjourned. —(Steve Double.)

Health and Care Bill (Twentieth sitting)

Alex Norris Excerpts

Committee stage
Thursday 28th October 2021 Public Bill Committees

[Dr Philippa Whitford (Central Ayrshire) (SNP)]

Obviously, smoking has increased during covid, particularly during the lockdowns, which is quite depressing after some of the progress made in recent decades. This array of new clauses tries to tackle the issue from different angles. New clauses 32 and 38 relate to the age at which someone can purchase, along with other point-of-sale policies. Those issues are all under devolved control, so I have not got involved in those. However, the policy decisions around manufacturing, flavourings, packaging and so on are all reserved, and all four nations of the UK would agree that the biggest single favour anyone can do for their own health is to give up smoking.

As older people and people who have smoked for many years sadly succumb to the diseases we know are caused by smoking, such as heart disease, stroke and cancer, it is incumbent on tobacco companies to recruit a new generation. That is what ornate packaging and childish flavourings are clearly aimed at doing, and they are therefore completely counter to the policies of the UK Government and the devolved Governments.

This is an opportunity to stake the point, move forward and take action to prevent the recruitment of young smokers into cigarette smoking, which will inevitably cost the NHS—indeed the four NHSs—more, as they deal with the health issues over a number of decades, than is raised by tobacco duty. The Government need to stop looking at what they earn from cigarettes and focus on minimising their use. That is the Government’s stated policy, and these new clauses would take that forward.

[Alex Norris (Nottingham North) (Lab/Co-op)]

It is a pleasure to resume proceedings with you in the Chair, Mr Bone. I commend my hon. Friend the Member for City of Durham for her new clauses and the powerful case she made for them, but also for her leadership in the all-party parliamentary group on smoking and health, alongside the hon. Member for Harrow East (Bob Blackman). I know it is a truly impactful APPG and I have always been grateful for my opportunities to go to its sessions to contribute or to listen, as I know Ministers have as well. Reducing smoking and being smoke free by 2030 is a major public health prize. It was a bit disappointing and surprising that there were no tobacco control elements on the face of the Bill, so it is right that we spend a little time trying to change that.

Successive Governments have rightly taken real pride in the reductions in smoking over the past 20 to 25 years. Those reductions have not happened by accident, but through concrete interventions that were sometimes controversial and often challenging at the time, such as the smoking ban, plain packaging and packet warnings—things that we soon afterwards realised were very impactful, and very much the right thing to do. Of course, as the hon. Member for Central Ayrshire says, we have to view this in the context of covid, and there has perhaps been a bit of backsliding on that progress, but that should drive us not to despair, but to redouble our efforts. I hope we can move things forward in the spirit that my hon. Friend the Member for City of Durham suggested.

We have to understand that the gains we have made in recent years come with a caveat. Most of the quitting has been done by people from better-off communities, and the benefits have largely accrued to those communities. We are now at the point where smoking accounts for 50% of health inequalities between the poorest and the best-off communities. If we really are serious about levelling up or whatever we want to call it, health is surely a crucial part of that. We know that smoking accounts for half of that difference, so we really ought to be focusing on it.

Reducing smoking ought to be a major project for any Government, because poorer smokers are just as likely to want to quit as their better-off counterparts, and just as able to do so if they have access to good services. However, we have spent a decade cutting those services in general, but particularly in the poorest communities, so high-quality smoking cessation services—which are so effective—have withered on the vine in many of the places that need them the most.

I will now turn to the new clauses tabled by my hon. Friend the Member for City of Durham, beginning with new clause 29. About one in seven adults smokes. That is about 7 million people, and while health warnings have been displayed on smoking packages for well over a decade, there is evidence that the impact of warnings such as those wane over time. However, the dangers of smoking remain high—between 2016 and 2018, there were 1,167 deaths attributable to smoking in my city of Nottingham alone—so we need to build on the techniques that have worked, with new ones to refresh our under-standing of the dangers of cigarettes to smokers.

There is evidence that dissuasive cigarettes can make smoking less attractive to younger people and non-smokers, and the inclusion of warnings on individual cigarettes, as proposed by new clause 29, is one key way of doing that. Such warnings are already being considered around the world: an in-depth study from France found that warnings on cigarettes increased negative health perceptions, reduced positive smoker image and the perceived pleasure of smoking, decreased the desire to start smoking, and increased the desire to quit. There are therefore signs that such a policy would be impactful.

New clause 30 deals with cigarette pack inserts. Inserting leaflets that contain health information and information about quitting is an effective and cheap way to target existing smokers and help them get support to quit. Those inserts are easy and cheap to implement and, moreover, while the reading of cigarette pack warnings decreases over time, the reading of inserts increases. In Canada, package inserts have been a legal requirement since 2000, and a survey of smokers in Canada found that between one quarter and one third of respondents had read pack inserts at least once in the prior month, and those intending to quit or having recently tried to do so were significantly more likely to have read them. Pack inserts will support and reinforce the impact of other measures that will require more significant investment campaigns to go with them, such as behaviour change campaigns and stop smoking services. They are a really good evidence-based, low-cost addition to such campaigns.

New clause 31 relates to the packaging and labelling of nicotine products. Over the decades, regulation has transformed traditional cigarette packaging, plastering it with warnings and preventing tobacco companies from selling a desirable image of smoking. However, regulations have not kept pace with the less traditional nicotine products, such as e-cigarettes and nicotine pouches. Tobacco companies are still able to sell e-cigarettes adorned with bright colours, cartoon characters and attractive images, as we have heard from my hon. Friend the Member for City of Durham and the hon. Member for Central Ayrshire, and I know that e-cigarette shops in my constituency offer vape liquids branded as vanilla ice cream, slushies and cookie dough, all of which appear targeted at young people, and children in particular.

I am enthusiastic about vaping—it still feels like that is an unfashionable thing to say, but I stand by it. I think vaping is a really good way to help people quit smoking and stay quit, and it is a really important part of a smoke-free 2030. However, it should be regulated properly to help make being smoke free a reality. Data shows that restrictions on the branding of e-cigarettes and refills reduce the appeal of vaping to young people, particularly children, while having little impact on adult smokers’ interest in using these products to quit smoking, so, again, it is cost-free.

[Dr Whitford]

I assume from the hon. Gentleman’s comments that he shares my concern that although vaping is considerably safer than traditional tobacco, as Public Health England reports on vaping show, vaping products still contain nicotine, which is a vascularly active substance. Therefore, we should still be concerned about non-smoking children being recruited on to vaping. We have no idea what decades of nicotine vaping will do to someone.

[Alex Norris]

I do share that view, particularly around children. Our preference would be for them to never start. There should not be packages with cartoons and child-friendly descriptors to develop a market among children. I think there would be a high level of consensus on that.

In that spirit, new clause 32 addresses an incredible loophole, which I cannot believe anybody thinks is a good idea. If the Minister is not going to accept new clause 32, I hope he will say when the issue will be resolved. The idea that you cannot sell e-cigarettes to children but that you can give them out as free samples to under-18s is quite hard to understand. It is time for us to get hold of this simple loophole, which goes against the spirit of the legislation, which is designed to protect children against nicotine addiction. I hope we can get some clarity, either because the Minister accepts the new clause or gives us a clear picture that we will see action very soon.

On new clause 33, about flavoured tobacco products, it again feels like the market is not acting in the spirit of the laws that have been passed. Flavoured tobacco is designed to make products more appealing, especially to younger people. In May 2020, we banned the sale of tobacco with a characterising flavour such as vanilla, spices and menthol. However, companies have adapted to this legal change with new innovations that skirt the law and provide smoking experiences that replicate flavoured tobacco. I can go to supermarket websites and find “green” branded cigarettes being sold, with many reviews stating how similar the flavour is to menthol cigarettes. I do not think that is in the spirit of the law.

In the year from May 2020, Japan Tobacco made over £91 million in profits from menthol brands. Clearly, the law has not worked as we want it to. Moreover, between January 2020 and 2021, a survey of smokers showed that the smoking of menthol cigarettes has not declined, despite the apparent ban, so I do not think the law is working. This new clause would do a good job of closing that legal loophole. If the Minister is not minded to accept it, I would be keen to know what the Government intend to do instead, because I cannot believe that they want laws that they passed, in possession of full facts, to be worked around in that way.

I will take new clauses 34 to 37 as a group, because they create the same thing: a tobacco control fund, paid for by manufacturers, combined with the regulation of tobacco companies’ profits. As my hon. Friend the Member for City of Durham said, when the Government announced their smoke-free 2030 ambition, they promised to consider a US-style “polluter pays” levy on the manufacturers, and included an ultimatum for industry to make smoked tobacco obsolete by 2030. My hon. Friend’s APPG has published a very strong option for how to do that. Ministers could lift and shift that very happily and get on with this. There are real benefits to that.

Action on Smoking and Health do some wonderful work, and I am grateful for its support in my work. It estimates that a comprehensive national, regional and local tobacco control programme—in many ways, we have lost that in recent years—to deliver a smoke-free 2030 would cost the UK about £315 million. That would involve adding back lost services. ASH’s estimate for a levy, based on the model the APPG talks about, is £700 million. This could be a “polluter pays” model, and we would have plenty left over to overturn all those poor public health budget cut decisions taken over the last decade. If the spirit of yesterday’s Budget was to try to rewind and erase the lost decade that we have had in this country, this would be a really good place to do that, and I think that is a good deal.

Of course, the EU tobacco tax directive is no longer a blocking factor, so we have complete agency to act in this area and it is in the gift of the Government, so I am very interested to know how far along the Minister or his colleagues are in the consideration, as they said, of this matter, and when we will see some proposals. Similarly, when will we see another tobacco control plan? That is something that everybody, from local government, public services, the private sector, community and voluntary services and all of us in this place, can organise around. The 2030 goal is a common goal. Pretty much everything that we have said in the new clauses are things that we are of one mind on. We can do something really good for the health of the nation, and I hope to find the Minister in action mode on that.

I will finish by referencing new clause 38, also tabled by my hon. Friend the Member for City of Durham, because I do not want it to look like I have ducked the question. It is important that we actively look at that and consider the evidence. I am perhaps not ready to say that it should be in the Bill, but it should be part of an active conversation in this area and part of a tobacco control plan. I think the Minister may be in a similar place on that, because we know that it is an effective part of the armoury. There are loads of really great things to go at in this set of new clauses, and I hope that he feels the same way.

[The Minister for Health (Edward Argar)]

It is a pleasure, as ever, to serve under your chairmanship, Mr Bone. I am grateful to the hon. Member for City of Durham for giving us an opportunity to debate the new clauses. I had the privilege and pleasure, I think almost a year and a half or two years ago, when I was standing in for the Public Health Minister, of responding to a debate in the House on this subject—I think she was in Westminster Hall responding to another debate. I therefore had the pleasure of listening to hon. Members speaking about the work of the APPG, and this issue more broadly, on that occasion. It seems like an age ago. I suspect that it was only about a year ago, but that is what the last year and a half has done for many of us.

New clause 29 seeks to provide powers for the Secretary of State to impose a requirement for tobacco manufacturers to print health warnings on individual cigarettes and cigarette rolling papers. That requirement is intended to further strengthen the current public health messaging and encourage smokers to quit. The Government are sympathetic to the aims of the new clause. We strongly support measures to stop people smoking and to educate smokers of its dangers, as we have done through warnings on cigarette packs. However, we believe that we need to conduct some further research and build a more robust evidence base in support of such additional measures before introducing them. If evidence shows that that requirement would not be effective, there is a risk that the power would not be used. As hon. Members will be aware—the hon. Lady was right in the point that she made—health is a devolved matter. Therefore such a measure would need to be considered in partnership with the devolved Administrations.

We are currently in the process of developing our new tobacco control plan. When the hon. Lady winds up the debate on this group of new clauses, she may say, “All well and good, but we’ve been in that place for a while. When will I see it?” I would be surprised were she not to do so. We continue to work on the plan at pace. She will be aware that the events of the last year and a half have, in a number of areas, knocked the existing timelines for producing plans slightly sideways, but we continue to work actively on that. As part of the tobacco control plan that we are working on, we are exploring a broad range of new regulatory measures to support our ambition to be smoke free by 2030. We are reviewing this specific proposal as part of that work, in considering the options for a package of legislative measures.

New clause 30 seeks to provide a power for the Secretary of State to introduce a requirement for manufacturers to insert leaflets containing health information and information about smoking cessation services inside cigarette packaging. We believe that that power is not strictly necessary as the Department could legislate to do that already under the Children and Families Act 2014, as inserts could be required for public health messaging through amendments to the Standardised Packaging of Tobacco Products Regulations 2015. It is also important to note that we already have strong graphic images and warnings of the health harms of smoking on the outside of cigarette packs, and the NHS website provides advice for people seeking to quit smoking. That website address is required on packaging under the Tobacco and Related Products Regulations 2016.

The current regulations, the Standardised Packaging of Tobacco Products Regulations 2015, prohibit the use of inserts, as there was limited evidence during the development of those regulations that placing public health messaging inserts inside cigarette packets was more effective than the messaging on the outside of packs. A post-implementation review of SPOT—if I may refer to the regulations in that way to save a little time—is currently under way. It is seeking to assess whether the regulations have met their objectives, and will identify whether there is a need to strengthen them in any way or to revisit any aspect of them, such as the one that the hon. Member for Central Ayrshire mentions. We aim to publish the post-implementation review before the end of this year.

If we were to introduce inserts through regulations, we would need to conduct further research on that. We would need to establish the public health benefit, costs to businesses, impact on the environment from litter and practicalities around enforcement, and crucially build a robust evidence base in support of such measures and their efficacy, along with, obviously, public consultation on them. This is something that we will consider as part of the Smokefree 2030 regulatory plans, but we will wait and see what, in the next couple of months, the published post-implementation review says. Health, as I have mentioned, is devolved, so it is something on which we would need to work with our friends and partners in the Scottish Government and other devolved Administrations.

New clause 31 seeks to enable legislation that would make provision about the retail packaging and labelling of electronic cigarettes and other novel nicotine products. That would include requirements for health warnings and the prohibition of branding elements that are attractive to children. I pay tribute to the work that the shadow Minister, the hon. Member for Nottingham North, has done in this space. I know that this is not just an issue of shadow ministerial concern for him, but something in which he has taken an interest as an individual Member of Parliament, so I recognise his expertise and knowledge in this area.

We are currently undertaking a post-implementation review of the Tobacco and Related Products Regulations 2016 as well. The current regulations include requirements on the packaging and labelling of e-cigarettes, along with restrictions on marketing, and they prohibit advertising on mainstream media such as TV and radio for e-cigarettes. Again, we will publish that review this year.

We want to encourage smokers to quit smoking using nicotine replacement therapy and by switching to less harmful products such as e-cigarettes. I take the point made by the hon. Members for Nottingham North and for Central Ayrshire. I share the shadow Minister’s view that if there is a choice between a conventional cigarette and an e-cigarette, I would much prefer people to be smoking an e-cigarette, because it is less harmful. But I absolutely take the point made by the hon. Member for Central Ayrshire, who is, as we know, an eminent clinician, that even if it is less harmful, it is still harmful. The ideal would be that people use neither product, but if it is a choice between the two and a question of getting someone to change their habit, I would much prefer to see them using an e-cigarette than a conventional cigarette. I think that there is consensus on that point across the two Front Benches and, indeed, the SNP Front Bench.

However, we need to ensure that our regulatory framework continues to protect young people and non-smokers from using e-cigarettes. That is the point about the degree of harm: although less, it is still there. Regular youth use of e-cigarettes does, on current evidence, remain very low, at about 2% of 11 to 15-year olds. That figure dates back to 2018, so it is slightly dated, but it gives us a useful data point. However, I do not believe that that should induce complacency in any of us. We need to continue looking at the matter very carefully.

Again, the Government are sympathetic to the aims of the new clause and strongly support measures to protect young people. Again, I point to the timing and the need for the post-implementation reviews and for further research and consideration in the light of those when they come forward in the next few months.

New clause 32 seeks to give powers to the Secretary of State to make regulations to prohibit the free distribution or sale of any nicotine products to anyone under 18, with the exception of the sale or distribution of nicotine replacement therapy licensed for use by under-18s. There is already in place, as the shadow Minister alluded to, legislation that prohibits the sale of tobacco and e-cigarettes to under-18s; that includes proxy sales. There are also existing powers in the Children and Families Act 2014 to extend the age-of-sale restrictions to include any nicotine products such as nicotine pouches. Therefore, as he said, the new clause is not needed in relation to sales.

New clause 32 seeks to further protect young people from the distribution of free nicotine products to under-18s, but again, we do not have a firm or robust evidence base at present to suggest that that is a widespread problem. The recent post-implementation review of the Nicotine Inhaling Products (Age of Sale and Proxy Purchasing) Regulations 2015, published earlier this year, did not raise that as a concern. I suspect the hon. Member for Nottingham North will say, “Why not get ahead of the game, anyway, with a pragmatic measure?”, and I have some sympathy with that point.

--- Later in debate ---

[Alex Norris]

I beg to move, That the clause be read a Second time.

I welcome the Government’s commitment to bring forth a consultation on introducing calorie labelling on alcohol products, for which we have been calling for some time, but I do not think there is a need to wait for this to be introduced in order for alcohol products to display the chief medical officer’s low-risk drinking guidelines, health warnings, ingredients and nutritional information, which is what the new clause asks for, mirroring what clause 127 does for food.

As it stands, there are no legal requirements for alcohol products to include health warnings, calorie information or even basic information such as ingredients. I am aware of the research by the Portman Group, which says that nearly half choose to do so. However, it is not quite cutting through. Consumers have a right to know what they are consuming and the associated risks, but many people are unaware of the calorie content in alcohol. About 80% of people are unable to identify the number of calories in a large glass of wine. Furthermore, beyond the most obvious risks of drinking alcohol, many people are unaware of the broader risks. Only a quarter of people are aware that alcohol is linked to breast cancer.

Similarly, despite alcohol’s link to worse pregnancy outcomes and serious lifelong impacts on a baby, one in three people are unaware that it is safest not to drink while pregnant, and it is estimated that 41% of women consume alcohol during pregnancy. That is a serious matter, and the issue of foetal alcohol spectrum disorder is not well known enough in this country. Especially in communities such as mine, I suspect that it has a profound impact on child development, which I know we will talk about shortly. My predecessor, Graham Allen, was a very strong proponent of a national study into FAS, and I echo his call. I really hope that might be something the Minister addresses, because it would have profound outcomes for child development and some of the care services that we might need in communities such as mine.

The public have a right to know what is in what they drink and eat and to make informed choices. I will not go round the bars snatching bottles of beer or glasses of wine out of people’s hands—I could not credibly do that, but I also have not inclination to do that. However, people should have a free and full understanding of the impacts of drinking alcohol and make their own judgments based on that. A recent survey conducted by YouGov found that 75% of people want the number of units in a product on the label, 61% want calorie information and 53% want the amount of sugar to be displayed. Again, this is what people want. Notwithstanding the research on some of the good things that the industry is doing voluntarily, which I pointed to earlier, we are still in a situation whereby that is not happening enough.

The Alcohol Health Alliance did a review of 424 alcohol product labels in London, the south-east and north-east of England, Wales and Scotland, which revealed that 71% of labels did not include the chief medical officer’s low-risk drinking guidelines. More than one quarter of labels included incorrect or misleading information that was either out of date or from other countries, 72% of labels did not list the ingredients and a majority had no nutritional information. Just 7% of labels displayed full nutritional information including calories, which is what we called for.

[Dr Whitford]

Many of the labels simply say, “Drink responsibly” or, “Drink aware”, but, as the hon. Gentleman is highlighting, the lack of information on labels introduces quite a complex step of that person having to go and look up the risk of harm or the unit measures. Yet we have just been debating the need to have warnings on cigarettes. Alcohol introduces harm both to the individual and, if they are heavy drinkers, to those around them, and therefore we should be taking this seriously. We have tried to do so in Scotland with measures such as minimum unit pricing, but information to the consumer is the first step.

[Alex Norris]

I am grateful for that intervention. I would certainly not talk down including the very broad messages that the hon. Lady mentions; I know that in an overwhelming number of cases that is available, but, as she says, that is not enough. People are conscious of that message and we should keep reinforcing it, but the jump-off point is, “So what? What am I going to do differently, or what do I need to understand differently?” At the moment, we are not helping them in that process.

This new clause, mirroring clause 127, asks the Secretary of State to introduce secondary legislation to compel the inclusion of this sort of information on products. It is a relatively modest ask, but it promotes informed choice, which in this area would be a very good thing. I do not think we should miss the opportunity to put it in the Bill.

[Edward Argar]

As has been set out, this new clause would make provision to ensure that alcoholic drinks display the chief medical officer’s low-risk drinking guidelines, a warning intended to inform the public of the danger of alcohol consumption, a warning intended to inform the public of the danger of alcohol consumption particularly when pregnant, a warning intended to inform the public of the direct link between alcohol and cancer, and a full list of ingredients and nutritional information.

First, let me say that alcohol labelling is an important part of the UK Government’s overall work on reducing alcohol harm. We believe that people have a right to accurate information and clear advice about alcohol and its health risks to enable them to make informed choices for themselves about their drinking. However, we feel that the new clause is unnecessary, because the Government are about to launch a consultation on these matters.

As part of our tackling obesity strategy, published in July last year, the Government committed to consulting on whether mandatory calorie labelling should be introduced on all pre-packaged alcohol, as well as alcoholic drinks sold in the out-of-home sector. The Government have worked with the alcohol industry to ensure that labels on pre-packaged alcohol reflect the UK chief medical officer’s low-risk drinking guidelines, and the industry has made some progress towards achieving that.

To make further progress, as part of our public consultation on alcohol calorie labelling we will also seek views on whether provision of the chief medical officer’s low-risk drinking guidelines, which include the various specific warnings that the hon. Gentleman mentioned, such as drinking in pregnancy and the drink-drive warning, should be mandatory or should continue on a voluntary basis. Respondents to the consultation will be able to provide suggestions for additional labelling requirements that they would like the Government to consider, such as nutritional information. As I said, that consultation will be launched shortly.

Clause 127 confers a power on the Secretary of State in England, and on Ministers in the devolved Administrations in Scotland and Wales, to make improvements to and amend or repeal articles of European Union Regulation 1169/2011. This EU regulation currently prohibits mandatory calorie labelling on pre-packaged alcohol that is 1.2% alcohol by volume and above. The passage of this legislation will therefore enable Governments to introduce changes such as mandatory calorie labelling on pre-packaged alcohol labels through regulations.

If a decision is made to mandate those labelling requirements following the consultation, the Bill will support the Government in being able to make the necessary changes through a new power in the Food Safety Act 1990. Consistent with the Government’s obligation to consult on matters concerning food law, before any regulations are made, a consultation with interested stakeholders must take place. Therefore, as there is a statutory duty to consult on introducing mandatory labelling requirements and as work on improving alcohol labelling is under way, we do not believe that a separate clause in the Bill is necessary at this time. I encourage the shadow Minister to be reassured by what I have said and to consider not pressing his new clause to a vote.

[Alex Norris]

I am grateful to the Minister for his response. Any measure, as with that in the new clause moved by my hon. Friend the Member for City of Durham, again relies on us waiting for consultation. It feels like an awful lot of consultation, which is of course an important part of doing the process right, but we should never confuse it with action. We have spent an awful lot of time in this space, and it feels as if there is a danger that we are into soft-pedalling territory, rather than action territory. Nevertheless, I heard what the Minister said, that it is an active process, so on that basis I will not press for a Division. We will reflect on the issue on the Labour Benches but, widely among those interested in the area, there is a growing sense of impatience. I hope that us giving the Minister and the Government space to continue the process is not confused with us being content that we are going quickly enough—I feel strongly that we are not. I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 43

Annual report on alcohol treatment services: assessment of outcomes

“(1) The Secretary of State must lay before each House of Parliament at the start of each financial year a report on—

(a) the ways in which alcohol treatment providers have been supported in tackling excess mortality, alcohol related hospital admissions, and the burden of disease resulting from alcohol consumption, and

(b) the number of people identified as requiring support who are receiving treatment.

(2) Alongside the publication of the report, the Secretary of State must publish an assessment of the impact of the level of funding for alcohol treatment providers on their ability to deliver a high-quality service that enables patient choice.”—(Alex Norris.)

This new clause would require the Secretary of State for Health and Social Care to make an annual statement on how the funding received by alcohol treatment providers has supported their work to improve treatment and reduce harm.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

The new clause would put a duty on the Secretary of State to make an annual statement on the spend on, and impact of, alcohol treatment services. Each day in the UK, 70 people die of alcohol-related causes. Alcohol is linked to 200 different diseases and injuries and costs the NHS £3.5 billion each year. Good alcohol treatment is essential to support those with alcohol dependence towards recovery. That is important for individuals and for the collective, because it reduces emergency services call-outs, unnecessary hospital admissions and avoidable deaths.

Despite the importance of treatment, even going into the pandemic, only one in five dependent drinkers were believed to be in treatment—that is 80% lacking healthcare. The incomprehensible and frustrating picture in this country in recent years, between 2016 and 2018, is that more than two thirds of local authorities in England cut their alcohol-treatment budgets, and in 17 of them those cuts were greater than 50%.

Having been a local councillor in that period, responsible for public health in my community, I know that no colleague did that because they thought it was the right thing to do for their community; they did it because the public health grant in this country has been run down over the past decade, which has been an absolute tragedy. Those are the sorts of services that we have lost.

A very visible example comes from St Mungo’s—we all know its wonderful work—which estimates that funding cuts have meant that 12,000 fewer rough sleepers accessed support in 2018-19 than would have done had funding remained at 2010 levels. The covid pandemic has only worsened the situation, leading to significant and sustained increases in the rate of unplanned admissions for alcoholic liver disease. This issue is very important now, in the very immediate term. We need to act.

Owing to resource cuts, however, many alcohol treatment providers have been forced to reduce their offer. A lack of outreach resources leads to people with some of the most complex needs missing out on support, while the reduction in capacity means that many of those at the lower levels, where an earlier intervention would be very impactful, miss out as well. Those with greater dependency are not getting specialised treatment or, in some cases, are not getting any treatment at all.

I strongly believe that the Bill needs to address the importance of alcohol treatment in terms of its funding and impact. Requiring the Secretary of State to report to Parliament on the ways in which alcohol treatment services have been supported and funded, and on the number of people requiring treatment and how that need is being met, will keep the issue at the forefront.

The Government’s own alcohol strategy states that alcohol treatment services

“offer the most immediate opportunity to reduce alcohol-related admissions and to reduce NHS costs.”

We also know that for every £1 invested in alcohol treatment £3 is yielded in return, rising to £26 over 10 years. Recovery also yields powerful dividends for families and communities affected by addiction, but at the moment we are going the wrong way in terms of our commitment to this issue. What I am asking for in the new clause, and I think it is a relatively modest ask, is for the Secretary of State to have on an annual basis an honest and candid assessment of the situation in this country, and then to account for the activity that is being taken to meet the need. It would be a very powerful statement that the Secretary of State and the Department have a grip of the issue and are committed to it, so I hope to find the Minister in listening mode.

[Edward Argar]

As ever, I am grateful to the shadow Minister for his exposition of the new clause, which would introduce a duty on the Secretary of State for Health and Social Care to publish an annual statement on how the funding received by alcohol treatment providers has supported their work to improve treatment and reduce harm. It would also introduce a duty on the Secretary of State to publish an assessment of the impact of the level of funding for alcohol treatment providers on their ability to deliver a high-quality service that enables patient choice. I join the shadow Minister in paying tribute to St Mungo’s for the work that it does, which I think we would all recognise across the House.

We do not think that a new reporting requirement introduced by the new clause is necessary as significant work is already under way in this area. Outcomes for local authority-funded alcohol treatment services are already published via the Office for Health Improvement and Disparities’ national drug treatment monitoring system. They are monthly and quarterly reports provided at a local authority level, and annual reports at a national level. The Office for Health Improvement and Disparities also publishes annual data on estimated numbers of alcohol dependent adults in each local authority in England. Health commissioners can use that resource to estimate the number of adults in their area who need specialist treatment, supporting them to appropriately plan and improve alcohol treatment services.

The Office for Health Improvement and Disparities provides a number of data tools to support local areas to compare their performance against that of other areas, and against national performance. Those tools include the public health outcomes framework, local alcohol profiles for England, and the spend and outcomes tool. With respect to spending, local authorities are currently required to report on their spend on alcohol harm prevention and alcohol treatment on an annual basis to the Department for Levelling Up, Housing and Communities. Part 2 of Dame Carol Black’s independent review of drugs was published in July 2021 and the Government, in their initial response, published on 27 July 2021, agreed to carry forward its recommendations and publish a new drugs strategy later this year.

The review recommended increased transparency and accountability from local authorities on how funding is spent. Although the subject of the review was drugs, the implementation of that recommendation will apply to both drug and alcohol treatment through mechanisms such as an improved commissioning standard, which is currently in development. I therefore encourage the shadow Minister not to press the new clause to a Division.

[Alex Norris]

I cannot quite accept that answer from the Minister. I understand the significant work that he talks about, and the different places where data is available. Those things tell us what is going on; they do not tell us why, and what we intend to do about it as a country. As a result, I do not think that is delivering for us, and we see that in the very difficult outcomes. On that basis, I am afraid I will have to press the new clause to a Division.

Question put, That the clause be read a Second time.

Health and Care Bill (Eighteenth sitting)

Alex Norris Excerpts

Committee stage
Wednesday 27th October 2021 Public Bill Committees

[Edward Argar]

I beg to move, That the clause be read a Second time.

New clause 62 adds to section 164 of the National Health Service Act 2006, enabling regulations to be made that would allow further products to be centrally stocked and supplied free of charge to community pharmacies without the need for reimbursement under the standard NHS arrangements. This would allow Ministers to create limited additional exemptions to the exemptions that can already be created by the regulation-making power introduced in 2017 for unlicensed medicines, more commonly known as “specials”.

As was recognised in 2017, the legislative framework for pharmaceutical remuneration established by section 164 is predicated on the basis that community pharmacies will be reimbursed for the products they supply. Unique conditions required the unlicensed specials medicines amendment to be tabled in 2017 due to an unconventional supply chain. Unusually, there was no competition and, therefore, no incentive for community pharmacies to seek value for money for unlicensed medicines.

Under normal conditions, a virtuous competitive circle would encourage community pharmacies to try to source the lowest cost product and, in doing so, force overall prices down. The 2017 amendment allowed for regulations to be made so that the process of sourcing the relevant products could be by central procurement and subsequently there could be direct supply to community pharmacies. No such regulations have yet been made, but the matter remains under review.

The amendment only seeks to further add, in a limited way, to the current powers to make regulations to provide for an exemption from the ordinary requirement to reimburse. The only products that it will cover are vaccines, pandemic treatments, and associated products such as diluents and syringes. There are various reasons why we may seek to procure centrally vaccines or products used to treat a pandemic, for example when the typical competitive supply chain and reimbursement arrangements cannot be relied on, because pressures from global demand mean that central purchasing and direct supply to community pharmacies is critical to maintaining continuity of supply for UK patients.

In those circumstances, if centrally purchased products, rather than being supplied directly to pharmacies, were sold to wholesalers, that would risk wholesalers exporting or selling the stock at a much higher price than is usually paid, thereby playing the market. In this example, that would defeat the original purpose of the central stockpile.

When supplying products directly to pharmacies free of charge, we do not want to reimburse pharmacies as well as purchasing the stock, as that would mean the Government or taxpayer paying twice. Currently, as I have indicated, the legislative framework only makes provision for the reimbursement price of specials to be set at zero. We are restricting those to vaccinations and immunisations, medicinal products used for the prevention or treatment of disease in a pandemic, and associated products. By carving out these niche, critical—but understandable, I hope—exceptions in the legislation in that way, we recognise the importance of not undermining the supply and reimbursement arrangements more generally and broadly across the piece. Furthermore, the legislation will also ensure that in the case of pandemic treatments, once the disease is no longer a pandemic, the appropriate arrangements will be put in place to transition back to normal supply and payment arrangements.

The new clause is important to ensure that centrally purchased stock of essential medicines intended for patients in England can be distributed to community pharmacies to meet clinical need and support patient access, whether that applies to a vaccination or treatment in connection with a pandemic. For those reasons, I ask the Committee to support the new clause.

[Alex Norris (Nottingham North) (Lab/Co-op)]

It is a pleasure to serve again with you in the Chair, Mrs Murray. As I said yesterday, we are grateful for the Minister writing with his explanation of this and the other new clauses ahead of time. That was helpful.

As the Minister explained in his letter, the new clause will simplify and safeguard the process of remuneration where the Government centrally procures vaccines, immunisations or products used to treat a pandemic, as well as other listed products, replacing “special medicinal products” under the previous legislation, in particular when there is significant international demand. That is very topical and we have a rich understanding of it given the events of the past 18 months, so it makes sense to the Opposition and we will not dwell on it long, nor will we press the new clause to a division. However, I seek clarity from the Minister on a couple of issues.

In the Minister’s letter, he cited the risk of wholesalers exporting the products or selling them at a much higher price if they were fed into the conventional supply chain. He characterised that as market failure. Community pharmacies would then be claiming reimbursement from the NHS based on the drug tariff determinations. I do not doubt the risk of that, and it is a foreseeable one, but am keen to hear from the Minister whether he is able to quantify the risk or demonstrate examples in either case. For example, during this pandemic, did that happen at the beginning? What was the cost if that took place? Have there been examples of profiteering preventing necessary products from reaching the patients for which they were intended?

In a second point, I am curious about the arrangements put in place to transition back to normal payment arrangements, once the disease in question is no longer pandemic or at risk of becoming pandemic. Again, I think we would always want restoration of normal circumstances at the first appropriate moment. In his letter, the Minister describes the arrangements as “appropriate”, while the new clause reads:

“Where…the Secretary of State considers that the disease to which it relates is no longer a pandemic disease or at risk of becoming a pandemic disease, the Secretary of State must revoke that provision within such period as the Secretary of State considers reasonable”.

Given that section 164 of the National Health Service Act 2006 also allows the Secretary of State to determine remuneration, that feels a little like the Secretary of State being allowed to mark their own homework. It could leave such measures in place for as long as suits them, rather than for as long as necessary, because the only determination of their need sits with that person. Will the Minister offer some reassurance that the power is for an emergency and is exceptionally limited, and give the Committee some comfort about the oversight and how Parliament perhaps will be given the chance to challenge the Secretary of State, so that the measures are not kept in place for any longer than necessary?

[Dr Whitford]

I have a small comment following on from the hon. Gentleman, who was asking for evidence of profiteering on specials. I was on the Committee considering the Health Service Medical Supplies (Costs) Act 2017 and brought the issue of specials before the Committee. These are often personalised medicines. In Scotland, they are produced centrally by the NHS, but there is certainly huge evidence of profiteering on them within NHS England, with hundreds of pounds being charged for simple ointments. While we may not have evidence on vaccines, evidence of profiteering on specials is long standing.

[Edward Argar]

I am grateful to the hon. Lady for helping to reduce the number of the shadow Minister’s questions that I need to answer. The hon. Lady makes her point well. We saw early on in the pandemic the challenges of a globally competitive market and the incentives and disincentives that can create around supply. I will not go into other aspects of supplies purchased for the NHS during the pandemic, but we have seen what happens when a market becomes super-saturated with demand versus a very limited supply, hence why we believe the steps in the new clause are prudent.

The shadow Minister will be familiar with approach in the new clause; it was used, for example, for covid vaccines, which were centrally secured and supplied directly to pharmacies. While we felt that supply could be justified on the basis of conventions of statutory interpretation that allowed us necessary flexibility in those exceptional circumstances, we think it is appropriate that we put such measures on a proper legal footing—through debate and, if necessary, Division in the House—to future-proof our arrangements. We are not trying to radically alter NHS pharmaceutical service provision or the payment mechanism. The aim is actually to strengthen the legal basis, and indeed the democratic oversight of that legal basis, through this debate in this Committee, for scenarios in which usual supply routes need to be bypassed.

The shadow Minister also raised a couple of other points, mainly about the Secretary of State’s power and Parliament’s role going forward, if I may paraphrase it in that way. I take his point. Judgments will obviously be based on advice from officials and legal and scientific advisers, but to a degree it is in the nature of ministerial accountability that there is an element of subjectivity when the Secretary of State is obliged to make a judgment. I appreciate the point, which I echoed in my remarks, on the need to turn these arrangements off or transition out of them as swiftly as possible, but we can see this pandemic declining and coming back at various times—that is the nature of the lifecycle of a pandemic; there are ups and downs before it finally burns itself out—and therefore the Secretary of State will ultimately need a degree of discretion and subjectivity in their judgment about the right moment, although obviously they will take advice.

On the House’s ability to challenge that, as the shadow Minister will possibly expect me to say, he and his colleagues and other Members will have ample opportunity, not only at Question Time but also, as I have discovered, through urgent questions, which I have answered on behalf of colleagues in the Government on occasion. There are plenty of opportunities for Members to summon Ministers to the Dispatch Box, or through written questions, to challenge and to probe and hold Ministers to account. I hope that hon. Members feel that this is a pragmatic and proportionate measure to address something we have identified in the course of the pandemic as needing resolution, and in so doing to put it on a surer and clearer statutory footing.

Question put and agreed to.

New clause 62 accordingly read a Second time, and added to the Bill.

New Clause 1

Prohibition of virginity testing

“(1) A person is guilty of an offence if they attempt to establish that another person is a virgin by making physical contact with their genitalia.

(2) A person is guilty of an offence if they provide another person with a product intended for the purpose, or purported purpose, of establishing whether another person is a virgin.

(3) A person is guilty of an offence if they aid, abet, counsel or procure a person to establish that another person is a virgin by making physical contact with their genitalia.

(4) No offence is committed by an approved person who performs—

(a) a surgical operation on a person which is necessary for their physical or mental health; or

(b) a surgical operation on a female who is in any stage of labour, or has just given birth, for purposes connected with the labour or birth.

(5) The following are approved persons—

(a) in relation to an operation falling within subsection (4)(a), a registered medical practitioner; and

(b) in relation to an operation falling within subsection (5)(b), a registered medical practitioner, a registered midwife or a person undergoing a course of training with a view to becoming such a practitioner or midwife.

(6) There is also no offence committed by a person who—

(a) performs a surgical operation falling within subsection (4)(a) or (b) outside the United Kingdom; and

(b) in relation to such an operation exercises functions corresponding to those of an approved person.

(7) For the purpose of determining whether an operation is necessary for the mental health of a girl it is immaterial whether she or any other person believes that the operation is required as a matter of custom or ritual.

(8) This section applies to any act done outside the United Kingdom by a United Kingdom national or resident.

(9) A person who is guilty of an offence under this section is liable, on summary conviction, to imprisonment for a term not exceeding 12 months, to a fine, or to both.

(10) The court must refer the case of any person guilty of an offence under this section who is subject to statutory professional regulation for investigation by the relevant regulator.”.—(Alex Norris.)

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

[The Chair]

With this it will be convenient to discuss new clause 2—Prohibition of hymenoplasty—

“(1) A person is guilty of an offence if they undertake a surgical procedure for the purpose of re-attaching membrane tissue, creating scar tissue or otherwise attempting to re-create the hymen in the vagina of a patient.

(2) A person is guilty of an offence if they advertise the service of hymenoplasty or any service that purports to ‘re-virginise’ or otherwise re-create or re-attach the hymen of a patient by way of surgical procedure.

(3) A person is guilty of an offence if they aid, abet, counsel or procure a person to undertake a surgical procedure for the purpose of re-attaching membrane tissue, creating scar tissue or otherwise attempting to or re-creating the hymen in the vagina of a patient.

(4) This section applies to any act done outside the United Kingdom by a United Kingdom national or resident.

(5) A person who is guilty of an offence under this section is liable, on conviction, to imprisonment for a term not exceeding 5 years.

(6) The court must refer the case of any person guilty of an offence under this section who is subject to statutory professional regulation for investigation by the relevant regulator.”.

[Alex Norris]

I want to speak to new clause 1 in my name and seemingly in the name of half the House. With pleasure, we have reached the new clauses. A central theme runs through the new clauses that my colleagues and I have tabled. If the Government are adamant that now is the time for this Bill, and we have well-established issues with that, then given the significant and growing challenges facing health and social care in this country we really ought to put things in the Bill that will make a difference. Too much of what we have discussed over the previous 18 sessions—give or take—has been about structures and moving things around; this is fundamentally likely to make little to no difference on the frontlines to practitioners or the people that we work for. These new clauses, and the new clauses in general, seek to try and redress that balance and put things in the Bill that will make an impact in this country.

--- Later in debate ---

I hope that I have given the Committee a clear rationale for why, although we are entirely aligned on the new clause’s policy objectives and intent, there are a number of drafting and other factors that we need to work on a little. However, I am hopeful that in short order we will be able to bring forward legislation and clauses that will be satisfactory to both sides of the House.

[Alex Norris]

Let me come back briefly on a couple of issues. First, I am grateful for the contribution of the hon. Member for Central Ayrshire and, in particular, her point about non-medical practices dressed up as medical practices. That is a particularly insidious way to inflict abuse on another person, and I completely agree with her that that is an absolute violation—it is as totemic as that.

We will all have taken great encouragement from the Minister’s response. I am grateful for that. I associate myself with the comments he made about the hon. Member for North West Durham—I should have said that in opening. Between us, we will ensure that he sees a copy of the proceedings, and he can take great encouragement from what the Minister said.

It was particularly welcome to hear that the Government intend to legislate in this space, with the intent for that to be at the earliest opportunity. That is good news, and the Opposition will support them in that process. I gently say—I know he enjoys these exchanges—that we are currently considering primary legislation, so this is definitely the earliest opportunity. If there are moments for the Government to revisit this issue on Report or in the other place, he will find colleagues very welcoming of that.

I do not want to shatter the consensus that has grown by dividing the Committee, so I do not intend to press either new clause to a Division. However, on new clause 2, we will look at what the expert panel says. I will be interested to see the divisions in opinion—I have not been able to find them. We look at these things on their merit, but the commitment to see the report before Christmas was welcome and will give great heart to campaigners in this space. The Opposition look forward to seeing the proposals and will be keen to support them if they can achieve the goals that we seek. I beg to ask leave to withdraw the motion.

Clause, by leave, withdrawn.

New Clause 3

Annual parity of esteem report: spending on mental health and mental illness

“Within six weeks of the end of each financial year, the Secretary of State must lay before each House of Parliament a report on the ways in which the allotment made to NHS England for that financial year contributed to the promotion in England of a comprehensive health service designed to secure improvement—

(a) in the mental health of the people of England, and

(b) in the prevention, diagnosis and treatment of mental illness.”—(Justin Madders.)

This new clause would require the Secretary of State for Health and Social Care to make an annual statement on how the funding received by mental health services that year from the overall annual allotment has contributed to the improvement of mental health and the prevention, diagnosis and treatment of mental illness.

Brought up, and read the First time.

[Justin Madders]

I beg to move, that the clause be read a Second time.

The Minister referred to my longevity in post, which gives me the advantage of having had this debate with him previously. That does not make it any less important; in fact, the subject has only risen in importance in the intervening period. That is why the Opposition were pleased to put our name to the new clause, which was tabled by the hon. Member for Newton Abbot (Anne Marie Morris).

In March, the Centre for Mental Health reported:

“There are…many areas where parity of esteem has not yet been realised. Mental health problems account for 28% of the burden of disease but only 13% of NHS spending.”

Parity of esteem is the principle by which mental health must be given equal priority to physical health. Many of us assumed that it had always been there, but debates have gone on over the years and, as that figure suggests, it is still some way from being achieved. The founding National Health Service Act 1946 spoke of a comprehensive health service, securing the improvement of both physical and mental health, and the National Health Service Act 2006 said the same. That principle was enshrined in the Health and Social Care Act 2012—at least, the parts of it that remain.

In operational terms, the Government require NHS England to work for parity of esteem for mental and physical health through the NHS mandate. However, there are reports that this requirement falls down at a local level. Certainly as a constituency MP, I have a whole range of stories of people not being able to access treatment in a timely manner, or being pushed around the system with very little effect and discharged from care before it was appropriate, with consequences we can all imagine. It is difficult to overestimate how challenging that is, not just for the individuals, but for the local commissioners when they face competing pressures.

We are not suggesting that the 20% to 30% gap should be closed entirely, but we should be looking to at least get on the road towards delivering true parity. There was a missed opportunity earlier in this Bill when we suggested that one of the mandated positions on the integrated care board should be a mental health representative. Should that have been accepted, the ambitions behind the new clause would have been much easier to achieve. It is about not just getting on the road to financial parity, but actually changing the culture so that disparities can be addressed. It does sometimes seem that mental health is the Cinderella service: the one that gets cut first at the expense of the more visible services where people, understandably, can see if a particular service is shut down.

It should go without saying that it is part of the Secretary of State’s normal duties to promote mental health care, but that is something that has been sadly missing. While we do not want to get into an exact science on spending, we do think that much more can be done in terms of delivery and outcomes. Looking at some of the hard facts, it is clear how far we have to travel. One in four mental health beds has been cut since 2010; just last year, 37% of children referred by a professional to mental health services were turned away. That is a shocking statistic, and I am sure most Members will have similar stories from their own constituencies of people in desperate need of help—young people whose entire lives could change by getting the right help at the right time, but who are not able to access services despite there being an obvious clinical need.

That must change. We need parity to mean something in practical terms. We hope that the new clause would create a shift in culture by requiring the Secretary of State to lay a report before Parliament addressing whether the aim of parity of esteem has been delivered.

--- Later in debate ---

[Justin Madders]

I am grateful for the Minister’s comments. If the investment standard is being met across the board, perhaps it is the investment standard that needs looking at rather than the services themselves. We are all aware that there is a lot more to do in this area. As the Minister rightly says, no doubt we will return to it, so I beg to ask leave to withdraw the clause.

Clause, by leave, withdrawn.

New Clause 5

Support provided by the NHS to victims of domestic abuse

“(1) Each Integrated Care Board must—

(a) assess, or make arrangements for the assessment of, the need for support for victims of domestic abuse using their services;

(b) prepare and publish a strategy for the provision of such support in its area;

(c) monitor and evaluate the effectiveness of the strategy;

(d) designate a domestic abuse and sexual violence lead; and

(e) publish an annual report on how it has discharged its duties relating to the provision of services to victims of domestic violence under the Care Act 2014.

(2) An Integrated Care Board that publishes a strategy under this section must, in carrying out its functions, give effect to the strategy.

(3) Before publishing a strategy under this section, an Integrated Care Board must consult—

(a) any local authority for an area within the relevant Integrated Care Board’s area;

(b) the domestic abuse local partnership board appointed by the local authority for an area within the relevant clinical commissioning group’s area under section 58 of the Domestic Abuse Act 2021; and

(c) such other persons as the relevant local authority considers appropriate.

(4) For the purposes of subsection (4), “local authority” means—

(a) a county council or district council in England; or

(b) a London borough council.

(5) An Integrated Care Board that publishes a strategy under this section—

(a) must keep the strategy under review;

(b) may alter or replace the strategy; and

(c) must publish any altered or replacement strategy.

(6) The Secretary of State may by regulations make provision about the preparation and publication of strategies under this section.

(7) The power to make regulations under subsection (7) may, in particular, be exercised to make provision about—

(a) the procedure to be followed by an Integrated Care Board in preparing a strategy;

(b) matters to which an Integrated Care Board must have regard in preparing a strategy;

(c) how an Integrated Care Board must publish a strategy;

(d) the date by which an Integrated Care Board must first publish a strategy; and

(e) the frequency with which an Integrated Care Board must review its strategy or any effect of the strategy on the provision of other provision in its area.

(8) Before making regulations under this section, the Secretary of State must consult—

(a) all Integrated Care Boards; and

(b) such other persons as the Secretary of State considers appropriate.”—(Alex Norris.)

This new clause would require Integrated Care Boards to publish a strategy for the provision of support for victims of domestic abuse using their services and designate a domestic abuse and sexual violence lead.

Brought up, and read the First time.

[Alex Norris]

I beg to move, That the clause be read a Second time.

For Opposition Members in Committees of this type, as we assemble the issues that we prioritise in proceedings, we have to be a bit of a magpie and pinch things along the way, so I want to recognise that this new clause is pinched from the hon. Member for Newton Abbot. I am grateful to her for tabling this and for the level of thought that she put into the amendment, which is a very good one.

Earlier in the proceedings, we discussed integrated care board plans and their responsibility to engage with the Domestic Abuse Commissioner. I was grateful for the commitments that the Minister made. There was a common understanding that the health and social care system has a crucial role in both preventing and tackling domestic abuse and in supporting victims and survivors. That sounds self-evident, but we are not in that position in this country yet, and we could do much better. I hope we can build on that consensus with the new clause, which requires integrated care boards to publish a strategy for the provision of support for victims of domestic abuse using their services and to designate a domestic abuse and sexual violence lead.

I will not repeat the arguments that I made earlier regarding the scale of domestic abuse, but it is worth reiterating top lines, particularly the global statistics from the World Health Organisation, which show that 30% of women have experienced some form of physical and/or sexual violence by an intimate partner in their lifetime. In this country it is one in four, so it is of a similar order of magnitude. The Government’s own estimate is that it costs health services £2.3 billion annually. A common refrain from the sector, with which I meet a lot, as I did before coming to this place, concerns the impact it could make with a fraction of that money if it was put into statutory services or the services that it provides. We should think about that investment model.

In discussing the new clause, I want to take the opportunity to cover something that we have not previously considered, namely domestic abuse, which tends to be against women but also concerns people with disabilities. According to Stay Safe East, disabled people and, most specifically again, disabled women, experience higher rates of domestic abuse than those who do not have disabilities. Abuse against women with disabilities is likely to be more violent and to happen over a longer period before the victim discloses it or can access help. The really sad thing is that if the victim––who is living with a disability––is not heard, there is a significant risk that they will then be sent home by the system to be cared for, in the very loosest sense, by their abuser. None of us would want that but it is the sort of thing that happens at the moment because we do not have a strong enough grip. I hope that we can use the new clause and the Bill generally to take more active steps to address that problem.

There is clearly a significant need for specialist domestic abuse services, which are crucial to enable women’s recovery in particular. Often, such services take on the work of statutory services and provide vital advocacy for women facing health exclusion, particularly in respect of services supporting black and minoritised women. It came out strongly in the debate on what is now the Domestic Abuse Act 2021 that we need specific and specialised services for those who are at greatest risk of being excluded. We did not quite get there in those provisions. I confess to using every legislative and parliamentary opportunity to keep pushing at this because it is really important and we can do much better.

We know that medical staff receive some training in adult safeguarding and, in a few hospitals, even on domestic abuse and sexual violence. But the skills and time to communicate with people with, say, learning disabilities or cognitive issues, with deaf survivors or with very elderly people who might be less likely to disclose personal information are not always available, and certainly not universally. The new clause seeks to put the onus on the integrated care system to get organised around this, to specialise and to prioritise it. It should be a priority across the system.

[Dr Whitford]

Does the hon. Gentleman think that we also have a job to do socially in reducing the stigma? I have worked in casualty departments and as a surgeon facing women who had clearly been abused but were standing or lying there making excuses for their abuser and saying why it was their own fault. As well as women with disability, there are women with insecure immigration status or insecure financial status who have no money of their own and feel that they have nowhere to go. I support the principle here, but we have a much bigger job to do around domestic abuse, which is endemic across the UK.

[Alex Norris]

I am very grateful to the hon. Lady for that intervention and completely agree with everything she said. For my part, and that of many of our colleagues, our way to tackle all those different barriers is to seek to put this in every bit of legislation. Most domestic legislation touches on these issues.

What is pertinent to this debate is thinking about the barriers to reporting. One barrier is the fear of not being believed. Of course, there is a bigger fear around prosecutions, which the Minister took a personal interest in when he was a Justice Minister, but it is clear from the evidence that we are not making enough progress. We have heard lots of positive sounds from the Government but no concrete proposals for change. We could do much better there.

On the barrier of not being believed, one way to create a better environment for a survivor to disclose what has happened to them is by their knowing that the person they are talking to in that healthcare setting has had training and works in a system that prioritises the safe disclosure of abuse. That would do a lot to build confidence. On the hon. Lady’s point about migration status, it is important that we talk about that. It was a key theme in the Domestic Abuse Act. There must be safeguards in place so that the disclosure of abuse trumps immigration status. The practitioner that they work with must be someone whose role is to help them address those issues, not someone who will be speaking to the Home Office. That first knock on the door will be someone trying to help them deal with the abuse and its impact on their life; it will not be from someone trying to resolve their migration status. That is an important principle.

Returning to the new clause, meeting with a professional social worker who ought be trained in assessing risks, including domestic abuse, might be the significant moment that an older or disabled person discloses domestic or other abuse. If given time and asked skilful questions in a safe environment, the person may disclose or express their fears, knowing they can do so in a protect manner. But across the country, such interventions are not falling into place on their own.

Women’s Aid’s data shows that in 2019-20, no refuge services responding to its survey were commissioned by their CCG, and just 10% of community-based services were. This is a multi-agency issue. I fought very hard to persuade the hon. Member for South Derbyshire (Mrs Wheeler) when she was Housing Minister that there ought to be investment and support going into the services through local government. She took that on, which was a good thing. Local authorities alone cannot tackle this issue. The picture that emerges from the evidence is that health agencies are not delivering as they ought to.

To be clear on what our modest ask is, subsection (1) states that each board must

“assess, or make arrangements for the assessment of, the need for support for victims of domestic abuse using their services”.

That is pretty basic. Following that, it must prepare a strategy, monitor that strategy and have an annual report on it, but particularly, under paragraph (d), it must

“designate a domestic abuse and sexual violence lead”,

because we know that in organisations such as the police or health organisations, where they have designated such a person, that person has been impactful. Those are pretty basic requirements. On many occasions the Minister has said that the point of the system is to be a permissive one and to let local areas shape services in the interests of their population, depending on the challenges they face; but the reality is that this problem is in every community, and we ought to be clear to ICBs that we expect this kind of activity. Subsection (3) includes a modest ask for consultation, which is reasonable and desirable.

Women in particular, and all our communities, desperately need this issue to be given deliberate focused attention. There is a high degree of consensus on it, but that does not lead to action frequently enough. The appointment of a Domestic Abuse Commissioner, which we have discussed, was a welcome step, but from a health and social care perspective we need to do more in the system. At the moment, that is not happening. That is not because I think that commissioners, leaders and decision makers do not think it is important, but they have an awful lot on. This can be a hidden crime that goes on behind closed doors, and as such drops down the list of priorities because of the urgent pressures on them; but we cannot let it go. As well as the leadership that we try to display on a national scale, we must do more to encourage this on a local scale. In this case, that is in the strategies and plans of the ICBs. We should make sure that happens.

To conclude—this is in the same vein as what I said when we debated new clauses 1 and 2—we should in our remaining time seek to put in the Bill things that will change people’s health outcomes, and outcomes in life more generally. New clause 5 is one of those things, so I hope the Government are in listening mode.

[Edward Argar]

I put on record my gratitude to my hon. Friend the Member for Newton Abbot and to the hon. Member for Nottingham North for enabling this discussion to take place in Committee today. I find myself in deep agreement with the idea that the NHS can play a vital role in protecting vulnerable people and, as part of that, it must have strategies and processes in place for supporting victims of domestic abuse, sexual violence and other forms of harm.

The hon. Gentleman was kind to refer to my stint at the Ministry of Justice, when as Victims Minister I took a close interest in this issue with Dame Vera Baird, the former Member for Redcar, in her role as Victims’ Commissioner—I pay tribute to her—and with the Minister of State, Ministry of Justice, my hon. Friend the Member for Louth and Horncastle (Victoria Atkins). My hon. Friend and I worked on the early stages of the Domestic Abuse Act 2021, and she saw that work through—I had moved to this role by then—before receiving a well-deserved promotion. I took a close interest in this issue when I was in the MOJ, and hon. Members from across the House will have found that it is not forgotten or left behind; we always reflect on it and see how we can continue to play a part when in other roles.

The hon. Member for Central Ayrshire was right to highlight the challenges that many people feel. The stigmas are completely unjustified, but people feel them because of the nature of the abuse and the controlling and coercive behaviour to which they have been subjected. When I was at the MOJ, I discovered the limitations of legislation in this space. We can and should legislate in certain areas, but a lot of this is about how services work on the ground, how we talk about this as a society, and how we break down the stigmas. One of the key things that I took away from my time at the MOJ was that tackling domestic violence and abuse is not just the responsibility of the justice system or the NHS; it is our responsibility as a society. I hope I can reassure the shadow Minister. On some areas, we tend to find ourselves in agreement rather more than is perhaps good for either of our political careers, but on this I entirely share his sentiments.

Turning to new clause 5, I hope to reassure the Committee that placing in the Bill a formal duty on ICBs to develop a separate strategy is unnecessary and not the best approach, but I hope the Committee will allow me to expand on my reasoning. There are already several duties on CCGs to consider the needs of victims of violence, including victims of domestic abuse, through the joint strategic needs assessment process. CCGs must respond to identified needs through health and wellbeing strategies. The duties will be transferred to and continue to apply to ICBs once CCGs are abolished, and will be further strengthened by the requirement on ICBs to develop system level commissioning plans. Through the Government’s landmark new Domestic Abuse Act 2021—it would be churlish of me not to recognise the Opposition’s work on it—local healthcare systems will be required to contribute to domestic abuse local partnership boards.

I slightly caution against requiring ICBs to create further additional strategies and plans, separate from those already in the Bill. I recognise the impulse to require NHS bodies to do this, because the theory is that a separate strategy will attract particular attention. My note of caution is because in doing so, we are saying, “We will put that over there, in that strategy” rather than having it as a thread that runs through all the strategies, underpinning strategic documents and plans of the local NHS and the ICB. We risk separating it and putting it in a different compartment from the wider span of integrated responsibilities, which is where it should sit.

The new clause also places a requirement on ICBs to have a domestic abuse and sexual violence lead. We agree with the principle, but we believe we can do that effectively through existing legislation and guidance. As set out in the Government’s recent violence against women and girls strategy, the Department of Health and Social Care will be engaging with integrated care systems and providing guidance to promote best practice in addressing violence against women and girls, domestic abuse and sexual violence. That could well include advice on designated leads and those internal structures and processes.

Beyond ICBs, I see a huge opportunity for integrated care partnerships to support improved services for victims of domestic abuse, sexual violence and other forms of harm through better partnership working. I am sure we have all undertaken visits to women’s refuges or to other charities that support women who are victims of domestic abuse. I should just say that it is, of course, true that men and women can be victims of domestic abuse. I refer to women in this context because an overwhelming number of victims are women, but it can happen to anyone, irrespective of gender.

In my previous role, I had the privilege of meeting survivors of domestic abuse, who were willing to talk to me about what had happened and their recovery from and survival of domestic abuse. In those conversations, people would often say, “I dealt with one agency, but it did not talk to this agency and this bit did not join up.” There is a real opportunity for the ICPs to work with housing providers, local authorities, the NHS and other voluntary and third sector organisations to help to bring together a more coherent and joined-up approach.

More broadly, I assure the Committee that the NHS will be at the forefront of stepping up to its responsibility to play its part in tackling domestic abuse, sexual violence and violence against women and girls. NHS England is developing enhanced trauma-informed mental health support for victims with the most complex needs within the sexual assault and abuse pathway. The DHSC’s new office for health promotion will work with the newly merged NHS England to review and build on workforce policies to ensure safe, effective processes are in place to support staff affected by domestic violence and sexual violence.

I hope I have reassured the Committee that we take this issue extremely seriously. Although we do not think that the approach proposed in the new clause is the right one, I am open-minded and happy to work across the aisle to see if there is more we can do in this space, in keeping with the strategy set out by my hon. Friend the Member for Louth and Horncastle when she was at the Home Office, and to see if there are other ways to achieve essentially the same objective.

[Alex Norris]

I have listened carefully to what the Minister has said, and I agree with significant elements of it. I take the point about existing duties on CCGs, and I am very mindful of those. The reality is that they do not work, or they certainly have not worked to date. I have no confidence that anything will change if current arrangements are just ported over to integrated care boards, which is what will happen. I do not think anything will change. I cannot imagine what will have changed in that moment to make it different, and I cannot therefore agree with the characterisation that the new clause is unnecessary.

I accept that we would not want to see a proliferation of further strategies. By making it a requirement, the new clause seeks to put the treatment, assessment and care of domestic abuse on the same footing in integrated care as elective care or major diseases. It should have that status, and at the moment it does not. It needs to be elevated to that level. I do not disagree at all with the Minister’s point about domestic abuse being a thread that runs through all policies. The reality is that we have been saying that for a really long time. What actually happens is that it is in everything and, as a result, it is in nothing, and things do not change. Certainly, they are not changing quickly enough in the health space.

Finally, on the point about integrated care partnerships, I hoped that the Minister would not say what he did, because that is the problem. The fundamental issue is that those who are making the direct daily decisions about health and care in our communities are downgrading the issue by considering what they do not as operational, daily, immediate, crucial decisions—in the way they would with elective care or cancer care—but instead as partnership work.

I would never talk down the pledges that we sign or the awareness days we do. I have signed all the pledges and gone to all the awareness days, and I will keep doing that because it is an important way of keeping the pot boiling. However, I am not convinced that they have done enough to make my constituents safer or give them a better health service. I have seen no evidence of that yet. This is not partnership work, but daily, crucial work that ought to be done by system decision makers, who ought to be prioritising it every day, but I do not think that is the case.

[Edward Argar]

If I was unclear, I apologise; that was not the intention of what I was saying. I sought to say that that partnership work brings together organisations that, I believe, do focus on the issue day to day and have it as an operational priority, but often still operate in silos. In some of the best partnerships in the best local authority areas, those silos are much less evident. My point about the ICP was not as an alternative to making this front and centre, and asking “What are you doing in your operational decision making?”—be it about elective care, cancer or domestic abuse, and treating them the same—but that often it operates in a way that is internal to those organisations, rather than across them.

That was the point I was trying to make about partnership: not only do we need that internal process and urgency—I totally share the hon. Gentleman’s view on that—but we need the ICPs to offer an opportunity to do that by bridging organisations. I hope that adds a little clarity, if I was unclear.

[Alex Norris]

It does, and of course I would not want to misrepresent what the Minister said. My point is that, while of course we should seek to work across the partnership and have a cross-partnership approach to tackling this issue in our communities—that is a very good thing to do—the problem currently is that that means we are not doing enough in the health and care space. There has to be something that says to health leaders, “Yes, work in partnership, but there are bits that you have to do yourselves that at the moment you are not doing well enough, so please do them.” This is my “something”. That was my logic in tabling this new clause, and it is why I intend to push it to a Division.

Question put, That the clause be read a Second time.